Computational methods applied to drug discovery: the rational design of dual inhibitors of FAAH and COX by Morgillo, Carmine Marco
UNIVERSITÀ DEGLI STUDI DI NAPOLI “FEDERICO II” 
 
 
 
	  
 
                           DIPARTIMENTO DI FARMACIA 
 
 
 
Dottorato di Ricerca 
in Scienza del 
Farmaco XXVIII 
ciclo 
 
 
Computational methods applied to 
drug discovery: the rational 
design of dual inhibitors of FAAH 
and COX 
 
 
 
 
     PhD Candidate:  CARMINE MARCO MORGILLO 
     Supervisor:    Dr.  BRUNO CATALANOTTI                                
     Co-tutor:           Prof.  F. JAVIER LUQUE 
     Coordinator: Prof. MARIA VALERIA D’AURIA 
 i 
 
 i 
 
 
 
 
 
 
 
“– Dico a voi, ehi, paladino! – insisté Carlomagno.  
– Com’è che non mostrate la faccia al vostro re? 
La voce uscì netta dal barbazzale.  
– Perché io non esisto, sire. 
– Mah, mah! – fece Carlomagno.  
– E com’è che fate a prestar servizio, se non ci siete? 
– Con la forza di volontà, – disse Agilulfo, – e la fede nella nostra santa 
causa!” 
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Abstract 
The search for effective and safe drugs in pain-relief treatment represents a 
great challenge for medicinal chemists. Lipid derived mediators, such as 
endocannabinoids, may have different roles as agonists of cannabinoid 
receptors, relieving pain, or as substrates of cyclooxygenase (COX), 
generating the pro-inflammatory prostamides. Moreover, the tissue-protective 
endocannabinoid anandamide is metabolised by fatty acid amide hydrolase 
(FAAH). Therefore, a new challenging approach in pain-relief might be the 
development of dual action FAAH/COX inhibitors.  
The purpose of this thesis is to apply computational methods in drug 
discovery to assist medicinal chemistry studies targeting the rational design of 
novel FAAH/COX inhibitors, and to exploit structural studies relative to two 
side projects on other biological targets. 
The wider project of this thesis explores the mechanism of action and the 
rational design of novel FAAH/COX dual inhibitors. The reversible mixed-
type inhibitors Flu-AM1 and Ibu-AM5, derivatives of flurbiprofen and 
ibuprofen, respectively, retain similar COX inhibitory properties and are more 
potent FAAH inhibitors than the parent compounds. Applying a combination 
of molecular docking, MD simulations and free energy evaluation of the 
ligand-receptor complex, the binding mode of the enantiomer forms of Flu-
AM1 and Ibu-AM5 has been found in the substrate access channel of FAAH 
and has been supported by studies of site-directed mutagenesis. The 
substitution of the isobutyl group of Ibu-AM5 with 4-(2-
((trifluoromethyl)pyridin-4-yl)amino group led to the design of TPA5 
derivative, which showed an inhibitory activity (IC50 = 0.59 µM) similar to 
the lead compound (Ibu-AM5, IC50 = 0.52 µM). Kinetic studies of TPA5 
revealed that it is a pure competitive inhibitor of rat FAAH and molecular 
modeling studies supported a binding mode that overlap the anandamide 
analog MAFP. Among TPA5 derivatives, compound TPA27 exhibited a 10-
fold enhancement in the inhibitory profile against FAAH (IC50 = 0.058 µM). 
Thermodynamic Integration calculations performed to complete the 
transformation of TPA5 in TPA27 yielded a free energy difference of 0.3 
kcal/mol, which indicates a slight lower affinity of TPA27 with respect to 
TPA5, in the competitive binding site. Kinetics studies showed that TPA27 
could be considered the first non-competitive reversible FAAH inhibitor 
reported so far, and that it more likely binds to an allosteric site.  
Differences in the inhibitory potency against rat and mouse FAAH for all 
compounds studied suggested different aminoacid composition of both 
competitive and non-competitive binding sites. This information was used as 
criteria of selection for a putative allosteric site found between the cytosolic 
port and the interface of the FAAH monomers. Computational studies in the 
allosteric site allowed the definition of the binding mode of Ibu-AM5 and 
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TPA27. Nevertheless, a series of derivatives of Ibu-AM5 and Flu-AM1 were 
designed in order to get more information on the structure-activity 
relationships, leading to the identification of novel derivatives with improved 
activity against FAAH (Ibu-AM56, IC50 = 0.08 µM; Ibu-AM57, IC50 = 0.1 
µM; Flu-AM3, IC50 = 0.02 µM).  
Finally, the thesis also reports the results of two other projects: i) the design of 
potential anticancer peptides that interfere in the formation of the tetrameric 
complex hUbA1/UbcH10/Ub2, key intermediate of the ubiquitination 
cascade.; ii) structural studies on the hybridization of PNA of different length 
with miR-509-3p, involved in regulating the expression of the CFTR gene, as 
a way to validate a potential new strategy for the treatment of Cystic Fibrosis. 
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Abbreviations 
Abbreviations used for amino acids and designation of peptides follow the rules of the 
IUPAC-IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 1972, 247, 
977-983. Amino acid symbols denote L-configuration unless indicated otherwise. The 
following additional abbreviations are used: 
 
2-AG, 2-ArachidonoylGlycerol; 
3D, three-dimensional; 
ΔTM, deleted transmembrane; 
AA, Arachidonic Acid; 
ABP, Acyl-chain Binding Pocket; 
AD, Adenylation Domain; 
AEA, N-Arachidonoylethanolamine; 
Ago, Argonaute; 
CF, Cystic Fibrosis; 
COX, Cyclooxygenase; 
CP, Cytosolic Port; 
FAAH, Fatty Acid Amide Hydrolase; 
FAE, Fatty Acid Ethanolamide; 
FCCH, First Catalytic Cysteine Half-domain; 
GALS, Lamarckian Genetic Algorithm; 
hFAAH, human FAAH; 
h/rFAAH, humanized rat FAAH; 
MAC. Membrane Access Channel; 
MAFP, Methyl Arachidonyl Fluorophosphonate; 
MD, Molecular Dynamics; 
mFAAH, mouse FAAH; 
MM, Molecular Mechanics; 
MM/GBSA, Molecular Mechanics Generalized Born Surface Area; 
MM/PBSA, Molecular Mechanics Poisson Boltzmann Surface Area; 
miRNA, microRNA; 
mRNA, messenger RNA; 
NSAID, Non-Steroidal Anti-Inflammatory Drug; 
OEA, N-Oleoylethanolamine; 
ON, Oligonucleotide; 
PB, Poisson-Boltzmann; 
PDB, Protein Data Bank; 
PEA, N-Palmitoylethanolamine; 
PG, Prostanoid; 
PGE2, Prostaglandin E2; 
PGI2, Prostacyclin; 
PNA, Peptide Nucleic Acid; 
PPARα, Peroxisome Proliferator-Activated Receptor α; 
QM/MM, Quantum Mechanical Molecular Mechanics; 
rFAAH, rat FAAH; 
RMSD, Root Mean Square Deviation; 
SA, Surface Area; 
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SAR, Structure-Activity Relationships; 
SCCH, Second Catalytic Cysteine Half-domain; 
ScUbA1, Saccharomyces Cerevisiae UbA1; 
SIE, Solvated Interection Energy; 
SMD, Steered Molecular Dynamics; 
spUba1, Scizosaccharomyces Pombe UbA1; 
TI, Thermodynamic Integration; 
TPA, 2-(4-((2-(Trifluoromethyl)Pyridin-4-yl)amino)phenyl)propan Amides; 
TRPV1, Transient Receptor Potential Vanilloid type-1; 
TXA2, Thromboxane A2; 
Ub, Ubiquitin; 
Ub(A), Activated Ubiquitin; 
UbA, Ubiquitin Activating enzyme; 
Ubc, Ubiquitin Conjugation enzyme; 
Ub(T), Thioester-linked Ubiquitin; 
UFD, Ubiquitin Folding Domain; 
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RATIONAL DESIGN OF DUAL INHIBITORS OF 
FAAH AND COX 
1. Introduction 
1.1 Connections between pain and inflammation 
The current treatment for acute and chronic pain consists in the administration 
of different classes of drugs acting through distinct molecular mechanisms 
involved in pain generation, such as i) agonists of opioid receptors, ii) 
gabapentinoids, which inhibit voltage-dependent calcium channels (VDCCs), 
and iii) nonsteroidal anti-inflammatory drugs (NSAIDs), which are inhibitors 
of Ciclooxygenase (COX), an enzyme involved in the generation and 
propagation of inflammation. These drugs are subject to some limitations due 
to common side effects that poses difficulties in the handling of the dose, and 
to the possibility to induce addiction or dependence as in the opioids case. 
Albeit in the last decades substantial advances in the pain-relief treatment 
were made, the search for effective and safe drugs still represents a great 
challenge for medicinal chemists., As an example, one can mention 
inflammation bowel disease, where pain conditions arise from non-resolving 
inflammation [1], which involves complex mechanisms and many different 
actors. Among them, lipid-derived mediators, such as prostanoids, may 
promote and maintain pain and inflammation. Other lipid derived mediators, 
such as endocannabinoids, may have different roles as agonists of cannabiods 
receptors, relieving pain, or as substrates of COX, generating the pro-
inflammatory prostamides. As suggested by numerous evidences, functional 
and biochemical interactions support the existence of a cross-talk between 
endocannabinoids and prostanoids signalling pathways [2]. Since the two 
most studied endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-
arachidonoylethanolamine (anandamide, AEA) present some redundancy in 
the way they are metabolised, a new challenge might be the development of 
multitarget drugs, inhibiting fatty acid amide hydrolase (FAAH) and 
cyclooxygenase (COX) as molecular targets for pain-relief and anti-
inflammatory therapy. 
 
1.2 Interacting pathways between endocannabinoids and prostanoids 
2-AG and fatty acid ethanolamines (FAEs) such as AEA, N-
palmitoylethanolamine (PEA), and N-oleoylethanolamine (OEA) (Fig. 1), are 
a family of signalling lipids involved in the regulation of a wide range of 
physiological and pathological processes, including pain and inflammation. 
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Figure 1: Chemical structure of the substrates of FAAH. 
 
AEA modulates nociception and mediates the majority of its biological effects 
acting as an endogenous agonist of G-protein coupled CB1 and CB2 
cannabinoid receptors [3]. During inflammation, activation of cannabinoid 
receptors results in attenuation of neutrophil migration and immune-cell 
recruitment, [4]. Moreover, AEA also targets the transient receptor potential 
vanilloid type 1 (TRPV1) but the effects of this interaction remains unclear 
[5]. 
OEA and PEA exhibit little activity at cannabinoid receptors, but may affect  
nuclear peroxisome proliferator-activated receptor-α (PPARα) and, to a lesser 
extent, GPR119 [6]. 
FAEs are produced from phospholipid precursors in membranes by very 
different pathways on the basis of their physiological demand. Therefore, the 
signalling activity of these substances is strictly dependent on the enzymes 
responsible for their formation and degradation [7]. AEA is mainly 
hydrolysed by FAAH into arachidonic acid (AA) and ethanolamine [8], while 
2-AG is also FAAH substrate, but is mostly inactivated by monoacylglycerol 
lipase (MAGL) [9] (Fig. 2). 
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Fig. 2: Simplified scheme of the endocannabinoid and prostanoid signalling pathways with 
some nodes of biological interactions (from ref. 1).  
 
FAAH inhibition will lead to increased concentration of AEA, and therefore 
the development of FAAH inhibitors has been examined in the search of 
novel strategies to reduce neuropatic pain. This strategy was proven to be 
effective in many animal modes, as exemplified in the work by Sharkey and 
coworkers, who showed that the use of selective FAAH inhibitors reduced the 
inflammatory symptoms in animal models of intestinal inflammation [10]. 
COX is membrane-bound enzyme that catalyses the cyclooxygenation of 
arachidonic acid (AA) in a variety of pro-algesic and inflammatory 
eicosanoids that includes prostaglandin E2 (PGE2), prostacyclin (PGI2) and 
thromboxane A2 (TXA2) [11] (Fig. 2). These signalling molecules regulate 
important physiological and pathological functions through the activation of 
selective G-protein-coupled receptors, such as inflammation, mucosal 
protection, cardiovascular homeostasis and cancer [12]. There are two COX 
isoforms, COX-1 and COX-2, which share ~60% sequence identity. COX-1 is 
expressed in most tissues and is considered to be a constitutive enzyme, while 
COX-2 is normally expressed in brain, spinal cord and kidney and is 
considered an inducible enzyme [13]. COX-2 expression increases in innate 
immune response and other host defence mechanisms during tissue damage or 
inflammation in response to cytokines, mitogens and growth factors [14]. 
In particular, COX-2 mediates the transformation of the endocannabinoids 2-
AG and AEA into prostaglandin-glycerol esters and prostaglandin-
ethanolamides (prostamides, PG-EAs), respectively [15]. These products are 
pro-algesic agents and do not show interactions with prostanoid or 
endocannabinoid receptors [16], but their mechanism of action is still under 
investigation. Nevertheless, they represent a potential interplay between 
endocannabinoid and prostanoid signalling networks. Therefore, COX-2 
mediated transformations of AEA and 2-AG into pro-nociceptive and pro-
inflammatory substances have led to the hypothesis of the presence of 
multiple functional connections between endocannabinoid and prostanoid 
systems, which may offer new molecular targets in the development of 
multitarget FAAH/COX inhibitors. 
 
 4 
 
1.3 FAAH/COX dual inhibition efficacy in pain-relief treatments 
Traditionally, NSAIDs are used in the treatment of mild to moderate pain and 
in co-administration with opioids in the management of moderate to severe 
pain [17]. The clinical effects of NSAIDs are based on the inhibition of the 
two COX isoforms, COX-1 and COX-2, which catalyse the conversion of 
membrane-derived AA into the prostaglandin endoperoxides PGG2 and PGH2 
[18]. One of the major problems associated with the use of NSAIDs is the 
high incidence of gastrointestinal adverse effects, due to inhibition of the 
production of gastro-protective prostaglandins, and possibly to topical effects 
in the gastric epithelium [19]. Recently, the use of a highly selective FAAH 
inhibitor was found to reduce by almost an order of magnitude the dose of 
NSAID diclofenac required for analgesia in a model of visceral pain [20]. 
This study indicated that the analgesic actions of NSAIDs are enhanced in a 
synergistic manner by drugs that inhibit FAAH. In fact, by increasing AEA 
levels, FAAH inhibitors enhance the ability of this compound to control 
emerging nociceptive signals [21], such as those mediated by prostanoids, 
resulting in an overpotentiation of NSAID-mediated analgesia. Apart from the 
increase in the analgesic action of the NSAIDs, FAAH inhibitors reduce the 
frequency and severity of gastric side effects exerted by those compounds 
[22]. However, the recent failure of a selective FAAH inhibitor in clinical trial 
in patients with osteoarthritic pain [23] has demonstrated that the increased 
levels in AEA are suboptimal due to COX-2 transformation of this substrate 
to PG-EAs, owing to the pro-nociceptive effects of prostamide F2α [24]. 
Therefore, besides gastro-protective effects, combined FAAH and COX 
inhibition may guarantee the therapeutic effectiveness through additive or 
synergistic effects rather than the use of selective compounds for the 
treatment of pain [25]. 
 
Fig. 3. Targeting both FAAH and COX to treat pain and inflammation. In multiple 
inflammatory condition the elevated expression of FAAH and COX-2 may exacerbate 
inflammation by lowering levels of anti-inflammatory and tissue-protective anandamide 
(AEA), while concurrently increasing levels of arachidonic acid (AA) and its prostanoid (PG) 
metabolites. 
 
The co-administration of drugs, either given separately or as a 
multicomponent formulation, has the disadvantage that different rates and 
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processes in metabolism of the individual drugs can trigger a wide variation in 
delivered dosages, which opens a potential risk for drug interactions and 
thereby could affect the treatment outcome, showing unexpected side effects 
[26]. An alternative approach, termed “designed multiple ligands”, concerns 
the use of a single compound with efficacy towards both targets [27]. In this 
approach, the pharmacokinetic properties of the formulations will be less 
complex than in the multicomponent strategy, but a potential drawback is the 
loss of flexibility in dosing. Therefore, dual inhibitors of FAAH and COX 
may be a promising therapeutic strategy for providing superior efficacy and 
greater safety than current non-narcotic analgesics [28]. 
 
1.4 Structural characterization of Fatty Acid Amide Hydrolase 
FAAH is an integral membrane enzyme that hydrolyses the endocannabinoid 
AEA and related amidated signalling lipids. Being a member of the amidase 
signature superfamily of serine hydrolases [29] FAAH serves its hydrolytic 
function in alkaline conditions (optimum is pH 9.0), revealing a titrable group 
with a pKa of ~7.9 (presumably Lys142). Mutation of Lys142 creates altered 
pH rate profiles that are similar to those of histidine mutants in classical 
Ser/His/Asp proteases. Unlike other amidases, FAAH is characterised by a 
unique Ser/Ser/Lys catalytic triad [30], where Ser241 acts as nucleophile, 
Ser217 stabilises the formed negative charge, and Lys142 acts as active base 
for catalysis [31]. The three-dimensional (3D) structure of FAAH was firstly 
solved by X-ray crystallography in complex with the covalent inhibitor 
methyl arachidonyl fluorophosphonate (MAFP) bound to Ser241, thus 
demonstrating that Ser241 is the nucleophilic residue [32]. Scheme 1 shows 
the catalytic mechanism for the acylation step of amide hydrolysis, and Fig. 4 
shows that Ser241 was covalently attached to the phosphonate inhibitor, while 
the bridging Ser217 was hydrogen bonded to Lys142.   
 
Scheme 1: Proposed mechanism for the acylation step of amide hydrolysis catalysed by FAAH. 
Lys142, initially in a deprotonated state (A), abstracts a proton from Ser217, which in turn 
abstracts a proton from the Ser241 nucleophile (B). Attack of the nucleophile on the substrate 
carbonyl is proposed to occur in a coupled manner with proton donation from Ser217 to the 
nitrogen atom of the amide substrate (C). This latter step requires the coincidental donation of a 
proton from Lys142 to Ser217, resulting in the formation of an acyl intermediate where both 
Lys142 and Ser217 have returned to their initial protonation states (D). (from ref. 30) 
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Fig. 4: The catalytic triad of FAAH, bearing the Ser241 bound to the inhibitor 
metoxyarachidonoyl phosphonate (MAP). Distances among Ser241, Ser217 and Lys142 are 
shown in Å. (from ref. 30) 
 
Endogenous FAAH substrates, such as AEA, serve regulatory functions in the 
body and have been implicated in a variety of pathological conditions 
including pain, inflammation, sleep disorders, anxiety, depression and 
vascular hypertension, which explains the interest in the development of 
FAAH inhibitors [33]. FAAH is a homodimer and, in each monomer, the core 
structure adopts an α/β fold with a twisted 11-strand β-sheet in the centre and 
24 α-helices surrounding the sheet (Fig. 5A). The catalytic triad is located in 
the centre of the enzyme. Three principal channels spread out from the 
catalytic core (Fig. 5B), known as i) the membrane access channel (MAC), 
which points to the protein surface facing the membrane bilayer and is 
considered the channel that gives access to the substrate; ii) the acyl-chain 
binding pocket (ABP), which binds the substrate acyl chain during the 
enzymatic reaction; and iii) the cytosolic port (CP), which connects the active 
site to the cytosol, and therefore it may allow the entrance of water molecules 
to the catalytic centre and bring out the ethanolamine produced in the 
enzymatic hydrolysis. In the proximal portion of the active site, the MAC and 
the ABP merge into a single section. Together, MAC and ABP form a wide 
channel that is predominantly hydrophobic in nature on one side and 
moderatately polar on the other side. 
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Fig. 5: 3D structure and localization of FAAH (A, from ref. 30) and representation of the 
principal structural features (B, from ref. 44). Principal channels are shown in surface, while 
Phe432 and catalytic triad are shown in sticks.  
 
1.5 FAAH inhibition and current state of the art  
A variety of selective FAAH inhibitors have already been described and, 
judging from the reported patents, the development of high-throughput 
screening strategies for the enzyme [34], and the recent creation of a web 
server for binding affinity prediction of ketoxazole derivatives against FAAH 
[35], there is renewed interest in the development of FAAH inhibitors. 
Different structural classes of FAAH inhibitors have been reported including 
α-ketoheterocycles, carbamates, piperidine ureas, arylureas and others [36]. 
Several rat FAAH (rFAAH) or humanized rat FAAH (h/rFAAH) structures 
have been stored in the PDB database. The first X-ray structure of rFAAH 
was determined for the deleted transmembrane (ΔTM) enzyme in complex 
with an AEA analogue, the irreversible inhibitor MAFP at 2.8 Å resolution 
(PDB code: 1MT5) [32]. Given the multiple membrane association 
possibilities of FAAH [37], protein expression and purification have been 
challenging for the human isoform (hFAAH), which shares ~82% sequence 
identity with rFAAH. Therefore, due to the difficulties to solve the 3D human 
structure, a  h/rFAAH structure was solved at 2.5 Å (PDB code: 2VYA) in 
complex with the piperidine-based inhibitor PF-750. In this structure, six 
amino acids of the active site were mutated into those of the hFAAH enzyme 
(namely Leu192Phe, Phe194Tyr, Ala377Thr, Ser435Asn, Ile491Val, and 
Val495Met) [38]. The h/rFAAH structure showed similar structural features 
as rFAAH. A remarkable difference was the orientation of Phe432 at the 
interface between ABP and MAC pockets. The presence of different classes 
of inhibitors induce a rotation by about 80° along the Cα-Cβ axis of Phe432 
(for instance, PF-750 in the h/rFAAH structure vs. MAFP in the rFAAH, Fig. 
6A). Thus, the MAC pocket of h/rFAAH in presence of PF-750 was 
remarkably larger than in rFAAH. A more pronounced reshaping of the 
channels may be observed from the comparison of rFAAH bound to carprofen 
(PDB code: 4DO3 [39]) and MAFP, where the different orientation of Phe432 
lead to a wider channel in the case of carprofen binding, as from the smaller  
occupancy of the channel by carprofen (Fig. 6B). This led to the suggestion 
that the flexibility of Phe432 sidechain might help the FAAH substrate to 
switch into pre-active conformations for hydrolysis, located in either ABP or 
MAC during catalysis. Following the first h/rFAAH structure, several 
additional FAAH structures bound with different covalent inhibitors were 
determined, confirming the structural flexibility of Phe432 [38, 40-44]. 
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Fig. 6. Superimposition of the crystal structures of the rat FAAH covalently bound to methyl 
arachidonoyl fluorophosphonate (MAFP, 1MT5.pdb) with: A) h/rFAAH in complex with 
piperazine-based inhibitor PF-750 (2VYA.pdb); B) rFAAH in complex with carprofen 
(4DO3.pdb). The covalently bound MAFP (tan), PF-750 and carprofen (green) inhibitors, as 
well as the catalytic Ser241-Ser217-Lys142 residues (cyan) are shown in sticks. The two 
structures share a similar active site with one remarkable difference at the interface between the 
MAC and ABP channels, given by the rotation of the interface residue Phe432 (shown in 
space-filling representation). 
 
The first attempts to design FAAH inhibitors concerned the use of natural 
substrates of FAAH as a template. This generated the AEA analogue MAFP 
inhibitor and trifluoromethyl ketones. These series of FAAH inhibitors were 
characterised by the formation of a covalent bond with the nucleophilic 
Ser241, blocking the catalytic function as long as the inhibitor remained 
irreversibly bound to the enzymatic pocket. However, these classes of 
inhibitors were not selective, inhibiting other serine hydrolases. Later, several 
reversible inhibitors were discovered, such as α-ketoesters, α-ketoamides, and 
α-ketoheterocycles, including the highly selective OL135 [45]. Very recently, 
a new series of α-ketoheterocycles compounds, derived from the inhibitor 
OL135, have been described as irreversibly targeting a cysteine in the FAAH 
catalytic site (Cys269), while also forming a reversible covalent bond with 
Ser241 [46]. Another class of irreversible FAAH inhibitors was characterized 
by a carbamic moiety functionalized with aryl or alkyl group at their O- and 
N- termini [47, 48]. URB524 is the first potent compound identified in the 
carbamate-based inhibitors series (IC50 = 63 nM). Modifications in URB524  
led to the more potent URB597 (IC50 = 4.6 nM) [49]. Recently, a brain 
impenetrable member of this class of compounds was disclosed (namely 
URB937, IC50 = 26.8 nM), with substantial analgesic effects in animal models 
[21]. Crystallographic and theoretical studies have shown that carbamate-
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based inhibitors act via the formation of covalent bond with Ser241 [42, 50, 
51]. Replacing the carbamic group by the urea functionality has led to the 
discovery of a newer class of FAAH inhibitors [36]. This series of inhibitors 
showed similar behaviour compared to carbamate-based inhibitors, forming a 
covalent bond with Ser241. In particular, compounds bearing a cyclic 
piperidine/piperazine urea scaffold, such as PF-750 (IC50 = 16.2 nM), PF-622 
(IC50 = 33.0 nM) and urea JNJ1661010 (IC50 = 33 nM) [52], showed 
improved selectivity in the inhibition of FAAH [53].  
The profile of FAAH inhibitors seem appropriate for pain-relief, although a 
lack of effect after repeated administration has been reported in a preclinical 
model [54]. Even more striking is the failure of an irreversible inhibitor of the 
FAAH, PF04457845, in clinical trials for the osteoarthritis [23]. A possible 
explanation of this failure could be that although FAAH is blocked, the 
substrate AEA is consumed by COX-2, undermining the analgesic effect [55].  
 
1.6 NSAIDs derivatives as FAAH/COX dual inhibitors 
Another approach to pain relief therapy consists of the inhibition of FAAH 
and COX enzymes through a multitarget inhibitor. NSAIDs are known for 
their anti-inflammatory and painkiller actions, inhibiting COX enzymes. 
Furthermore, some NSAIDs (like ibuprofen, flurbiprofen, paracetamol and 
carprofen) are able to weakly inhibit FAAH (i.e. ibuprofen IC50 = 134 µM and 
flurbiprofen IC50 = 29 µM) [56, 57]. This finding provided a rationale for the 
design of molecules that carry multitarget FAAH and COX inhibitory 
activities. The development of single molecules with such a profile would 
exploit several advantages over combination therapies, including a more 
predictable pharmacokinetic profile and a decreased potential for drug-drug 
interactions. As a proof of concept, the groups of Prof. V. Onnis (Università 
di Cagliari, Italy) and Prof. C. J. Fowler (Umea University, Sweden) 
developed in 2003 a series of heteroaromatic ibuprofen anilides bearing 
substituted pyridine or pyrimidine groups, which showed improved analgesic 
activity and reduced gastrointestinal side effects relative to the parent acid 
[26]. In this regard, the N-3-methyl-pyridin-2-yl amide of ibuprofen (Ibu-
AM5) was found to be the best analogue. This compound produced very low 
ulcerogenic effects compared to its parent molecule, ibuprofen. In a 
subsequent study, a series of other amide analogues derivative of ibuprofen 
were generated. Ibu-AM5 and Ibu-AM14 resulted to be the most potent 
inhibitors of rFAAH relative to ibuprofen, showing IC50 values of 0.65 and 
3.6 µM respectively [58]. Moreover, ibuprofen, Ibu-AM5 and Ibu-AM14 
showed substrate-selective inhibition of COX-2, being poor inhibitors of the 
cyclooxygenation of AA by COX-2 and producing incomplete inhibition of 
this substrate. When AEA was used as substrate, these compounds were 
relatively potent inhibitors of COX-2, with IC50 values of ~6 (ibuprofen), ~19 
(Ibu-AM5) and ~10 µM (Ibu-AM14). Later, a small series of racemic 
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flurbiprofen and naproxen amide derivatives, bearing the same substitutions 
of Ibu-AM5, were also investigated [25]. Within this set, Flu-AM1 and Nap-
AM1 demonstrated increased inhibitory potency for rFAAH, relative to the 
parent NSAIDs (flurbiprofen and Flu-AM1 FAAH IC50 values of 29 and 0.44 
µM respectively; naproxen and Nap-AM1 FAAH IC50 values of > 100 and 
0.74 µM respectively). Moreover, the ability for these compounds to inhibit 
the cyclooxygenation of AA by COX-1 and COX-2 and the cyclooxygenation 
of 2-AG by COX-2 was also tested. A similar pattern of COX-1 and COX-2 
inhibition was observed between Flu-AM1 and parent compound, although in 
general 2- 3-fold higher concentration were required to produce the same 
effect as flurbiprofen (Flu-AM1: COX-1 AA IC50 = 6.6 µM; COX-2 AA IC50 
= 42 µM; COX-2 2-AG IC50 = 1.7 µM, respectively; flurbiprofen: COX-1 AA 
IC50 = 3.6 µM; COX-2 AA IC50 = 103 µM; COX-2 2-AG IC50 = 1.3 µM, 
respectively). By contrast Nap-AM1 was a rather poor inhibitor of both COX 
isoforms (COX-1 AA IC50 = 56 µM; COX-2 AA IC50 > 100 µM; COX-2 2-
AG IC50 = 6.3 µM, respectively).  
Very recently, a different strategy for the design of dual FAAH/COX 
inhibitors was proposed by the group of Piomelli and co-workers based on the 
integration of the alkyl carbamic acid group of the URB597 in the 
flurbiprofen structure. Among these derivatives, the compound ARN2508 
showed submicromolar activity against rFAAH, ovine COX-1 and human 
COX-2 [59]. However, this compound blocks irreversibly both FAAH and 
COX enzymes. 
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2. Aims of the study 
 
The main aim of the PhD project herein presented was the design of novel 
dual inhibitors of FAAH and COX.  
NSAIDs amide derivatives Flu-AM1 and Ibu-AM5 represented valuable leads 
for the design of novel dual inhibitors, considering their pharmacological 
profile and mechanism of action. Indeed, they showed an increased FAAH 
activity and comparable COX inhibition with respect to parent NSAIDs. 
Moreover, they are reversible inhibitors, showing a mixed type inhibition 
kinetics.  
Previous efforts aimed at improving the activity of ibuprofen amide 
derivatives using classical medicinal chemistry approaches allowed to define 
some structure-activity relationships, but failed to identify compounds with 
improved potency toward FAAH [26]. Therefore, in collaboration with the 
groups of Prof. V. Onnis and Prof. C. J. Fowler, we undertook a 
multidisciplinary study of the mechanism of action of Flu-AM1 and Ibu-
AM5. In particular, we were interested in understanding the molecular basis 
of the inhibition kinetics of these compounds. Indeed, different molecular 
mechanisms may result in a mixed type inhibition. The experimental findings 
that closely related ibuprofen amide derivatives might show different 
inhibition kinetics (Ibu-AM5 vs. Ibu-AM14) prompted us to investigate, with 
an approach including computational methods, enzymology, chemical 
synthesis and mutant expression, the hypothesis that the mixed inhibition 
showed by Ibu-AM5 and Flu-AM1 were due to the capability to interact with 
two distinct binding site with different affinity. 
In this context, computational methods offer unique opportunities to 
investigate the mutual structural rearrangements induced by ligand binding in 
the complex. We used an approach including a combination of molecular 
docking, molecular dynamics (MD) simulations and free energy methods. 
Hence, the study of the dynamical process of the formation of ligand-target 
complex would provide a molecular rationale for the design of more potent 
NSAIDs derivatives with FAAH/COX dual activity. Therefore, in order to 
design more potent FAAH inhibitors we investigated the binding mode of 
NSAIDs and related compounds, since little was known about the nature of 
interactions of these compounds with FAAH, or to the role of chirality in 
binding affinity. According with the inhibition kinetics, we started our 
analysis of the binding mode from the known competitive binding site, and 
we explored FAAH structure to search for potential allosteric binding sites.  
Eventually, since MD simulations render a series of structural ensembles, 
clustered based on structural similarities, we also used methods for the 
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evaluation of the free energy of the system in order to select the more 
favourable binding mode.  
Taken together these approaches will be used to analyse dynamical 
conformations of the complex induced by the ligand with the goal of 
discovering structural insight that might be useful to design novel 
FAAH/COX inhibitors. 
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3. Experimental section 
Direct interactions between compounds and FAAH were investigated 
combining molecular docking studies with MD simulations. The simulations 
were performed on the rFAAH with deprotonated Lys142, as proposed for the 
catalytic mechanism [30]. A preliminary validation of the computational 
protocol, was performed by reproducing the experimentally determined 
binding mode of the pyrrolopyridine inhibitor found in the crystal structure 
3QK5, which showed reliability of the procedure not only to reproduce the 
ligand binding, but also the position of key water molecules within the active 
site. 
 
3.1 Molecular docking 
Rigid docking calculations were performed using the software Autodock 4.2 
[60]. The 3D structures of compounds were generated with pymol. Docking 
was performed on a single monomer of rat FAAH (PDB code 3QK5) [61], 
after crystallized ligand removal. Rigid docking in the competitive binding 
site was performed using a cubic docking box of 603 grid points, centred on 
the position of the original ligand (3-{(3R)-1-[4-(1-benzothiophen-2-
yl)pyrimidin-2-yl]piperidin-3-yl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-
yl)acetonitrile. The grid for the rigid docking in the allosteric site was centred 
on the basis of the result of cavity screening on mouse and rat FAAH in a 
pocket between CP and the interface between FAAH monomers and the 
maximum size of the axes were set to 54 grid points. The rotable bonds of the 
compound were automatically detected by Autodock default parameters. For 
each docking run, 100 iterations were performed using default parameters of 
Lamarckian genetic algorithm (GALS). The results were clustered on the 
basis of RMSD criterion (≤ 4 Å). The representative poses of the best clusters, 
according to Autodock 4.2 score, of each system were used for further 
analysis. 
 
3.2 Molecular Dynamics 
MD simulations were performed to refine best docking results with Amber12 
[62]. To this end, the representative poses of the best clusters retrieved from 
docking calculations were loaded in the two monomers of the dimeric form of 
rat FAAH (PDB code 3QK5), after removal of the pyrrolopyridine derivative 
and water molecules.  
Each complex was immersed in a pre-equilibrated octahedral box of TIP3P 
water molecules, and the system was neutralized. The final systems contained 
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about 80000 atoms. All simulations were performed with the Amber 99SBildn 
force field [63] for the protein and the gaff force field [64] for the ligands. The 
charge distribution of the inhibitors was refined using RESP charges [65] 
fitted to the B3LYP/6-31G(d) electrostatic potential obtained with Gaussian09 
[66].  For each complex the geometry was minimized using convergence 
criterion for the energy gradient set to 0.01 kcal/mol·Å2 in three steps, which 
involve: i) hydrogen atoms in the system (5000 steps of steepest descent and 
10000 steps of conjugate gradient), ii) hydrogen atoms, water molecules and 
counterions (2000 steps of steepest descent and 18000 steps of conjugate 
gradient), iii) finally the whole system (2000 steps of steepest descent and 
18000 steps of conjugate gradient). Thermalization of the system was 
performed in four steps of 60 ps, increasing the temperature from 50 to 298 K. 
Concomitantly, the atoms that define the protein backbone were restrained 
during thermalization using a variable restraining force. Thus, a force constant 
of 30 kcal/mol·Å2 was used in the first stage of the thermalization and was 
subsequently decreased by increments of 5 kcal/mol·Å2 in the next stages. 
Then, an additional step of 250 ps was performed in order to equilibrate the 
system density at constant pressure (1 bar) and temperature (298 K). Finally, 
an extended trajectory was run using a time step of 2 fs. SHAKE was used for 
those bonds containing hydrogen atoms in conjunction with periodic 
boundary conditions at constant pressure and temperature, particle mesh 
Ewald for the treatment of long range electrostatic interactions, and a cutoff of 
10 Å for non-bonded interactions. The structural analysis was performed 
using in-house software and standard codes of Amber 12. 
A preliminary validation of the computational protocol was obtained by 
predicting the experimentally determined binding mode of the pyrrolopyridine 
derivative in the 3QK5 crystal structure. The non-covalent ligand of the X-ray 
structure was chosen as reference due to higher structural similarity toward 
our compounds with respect to carprofen. It is worth noting that 
computational procedure successfully reproduced the binding mode of the 
pyrrolopyridine inhibitor, as well as the distribution of water molecules 
around the ligand in the binding cavity. 
 
3.3 Free energies calculations 
Analysis of the MD trajectory was carried out by calculating MM/GBSA, 
MM/PBSA and SIE on a 0.1 ns interval at the end of the trajectories. 
QM/MM calculations were performed for a set of 50 snapshots taken on a 0.1 
ns interval along the last 5 ns of the trajectories, averaging the electrostatic 
and van der Waals components of the individual snapshots.  
3.3.1 MM/PBSA method 
The MM/PBSA method was used to calculate the free energies of molecules 
in solution including those related to protein-ligand binding, which enables 
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analysis of the stabilities of different patterns of interactions in protein-ligand 
complex formation [67]. We used open source AmberTools package 
(MMPBSA.py) [68] to perform binding free energy calculations. The energy 
constituents included molecular mechanics (MM), electrostatic contributions 
to solvation (PB), and nonpolar contributions to solvation (SA). The binding 
free energy for protein-ligand complexes was calculated based on the 
following equation (1) [68]:  
ΔGbinding = ΔGcomplex – ΔGprotein – ΔGligand   (1) 
where ∆Gcomplex represents the free energy of a ligand-protein complex, and 
∆Gprotein and ∆Gligand are the free energies of protein and ligand, respectively. 
The vacuum-potential energy, EMolecular–Mechanics, includes the energies of both 
bonded and non-bonded interactions and is calculated based on the molecular 
mechanics force field parameters [69], as shown in eq. 2: 
EMolecular–Mechanics= Ebonded + Enon-bonded  (2) 
where EMolecular-Mechanics represents the gas-phase energy, Ebonded represents 
bonding interactions consisting of the bond, angle, dihedral, and improper 
interactions. Non-bonded interactions, Enon-bonded, include both electrostatic 
and van der Waals interactions. 
In the MM/PBSA approach, the solvation free energy was calculated using an 
implicit-solvent model. The solvation free energy is given by the eq. 3: 
ΔGsolvation = ΔGPolar + ΔGNon-Polar  (3) 
where, ∆GPolar and ∆GNon-polar are the electrostatic and non-electrostatic 
contributions to the solvation free energy, respectively. The electrostatic term, 
∆GPolar, is estimated by solving the Poisson–Boltzmann (PB) equation. The 
non-polar solvation energy, ∆GNon-Polar is separated into attractive (dispersion) 
and repulsive (cavity) interactions. 
3.3.2 SIE method 
Sietraj is an alternative to the MM/PBSA software provided by the AMBER 
distribution. Solvated interaction energies (SIE) are calculated using 
parameters that have been fitted to reproduce binding free energies of a data 
set of 99 protein-ligand complexes [70]. Note that the underlying physics 
behind the electrostatic components of SIE and MM/PBSA is the same. 
Hence, all the caveats of implicit solvation apply. The main differences lie in 
the choice of parameters, surface generation method [71] and Poisson solver 
[72]. 
3.3.3 QM/MM calculations 
The contribution due to the formation of the ligand-protein complex in the gas 
phase was determined by QM/MM calculations. To this end, the ligand was 
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treated at the QM level and all the residues located at less than 15 Å of the 
ligand were treated classically. Accordingly, the electrostatic term accounts 
for the QM interaction (determined at the B3LYP/6-311+G(d,p) level) of the 
ligand with the set of point charges of the residues included in the MM region. 
The van der Waals term was determined using the 6-12 expression as 
implemented in AMBER. The contribution due to the solvation of the 
complexes (ΔGsol) was calculated by MM/GBSA and MM/PBSA methods. 
3.3.4 Thermodynamic integration 
The A1-mode binding of TPA5 in monomer A of rFAAH was used as starting 
structure for the free energy calculation using TI. The TI simulations of the 
alchemical transformation from TPA5 into TPA27 was separated into two 
parts: ligand transformation within the protein active site (ΔGbound) and ligand 
transformation in solvent (ΔGfree). The binding free energy difference between 
these two similar ligands [ΔΔG(A→B)] can be calculated from eq. (4): 
ΔΔG(A→B)= ΔGbindB – ΔGbindA – ΔGbound – ΔGfree  (4) 
We have performed one-step TI, since the van der Waals and electrostatic 
transformation of the unique regions between ligands A and B both occur in 
the same step. The simultaneous electrostatic and van der Waals 
transformation events in the one-step TI could result in high system 
instabilities, which is overcome in this study by activating both Lennard-Jones 
(eq. 5) and Coulomb Softcore potentials (eq. 6) simultaneously [73]. 
 (5) 
Softcore potential in van der Waals is activated to avoid any instability as 
atoms appear and disappear, where λ is a coupling parameter, rab is the atomic 
distance between two particles, ε is the Lennard-Jones potential well depth, σ 
is the distance where the two particles intermolecular potential is equal to 
zero, and α is the Lennard-Jones Softcore potential energy function curvature 
control parameter, which has previously been recommended to be α = 0.5 
[73]. 
  (6) 
Electrostatic transformation is mediated by softcore potential, where qa and qb 
are electrostatic charges of transformed atoms in two ligands and β is the 
Coulomb Softcore potential energy function curvature control parameter, 
which has previously been recommended to be β = 12 Å2 [73]. 
In the ΔGbound and ΔGfree steps, each step is divided into 9 windows with 
different coupling parameters (λ), where λ = 0 is the initial state and λ = 1 is 
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the final state. The energy in each step (ΔG) can be calculated using eq. (7) 
where the bracket represents the average of the potential energy of the studied 
system [σ(λ)] for the given λ value, which is calculated using the trapezoid 
integration method. The λ values in this study are taken from the Table 21.1 in 
the Amber reference manual [74].  
Each window was subjected to a 1000-step steepest descent minimization to 
remove bad initial contacts and a 50 ps NPT heating run in which the system 
temperature was raised to 298 K with a target pressure of 1 bar. Equilibration 
was followed by a 5 ns NPT simulation for data collection. Therefore, TI 
simulation required at least 90 ns MD simulation, since it include 2 
transformations of 9 windows. Therefore, TI calculations are a very expensive 
computational method.  
The following equation (7) was used to derive the MD simulation settings for 
each window. 
  (7) 
 
3.4 Homology building 
The amino acid sequence of mouse FAAH was retrieved from the Universal 
Protein Resource database (http://www.uniprot.org accession ID O08914). 
The 3D structure of the target protein was modelled using SWISSMODEL 
[75]. The X-ray determined structure of rat FAAH 3QK5 was used as 
template (covered sequence 100%; sequence identity of 91.7 %). 
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4. Inhibition of FAAH by the enantiomers of Flu-AM1 and 
Ibu-AM5 
4.1 Introduction 
Ibu-AM5 and Flu-AM1 are valuable leads for the design of novel dual 
inhibitors of FAAH and COX enzymes, due to their pharmacological profile. 
Both compounds, that are profens derivatives, retain a chiral centre as the 
parent compounds, but it is not known how this affects their ability to inhibit 
FAAH. Previously reported studies [56, 76-78]. Demonstrated pronounced 
enantioselectivity towards inhibition of FAAH of some classes of inhibitors. 
In consequence, we have faced the study of the interaction between the 
enantiomers of Ibu-AM5, Flu-AM1 and FAAH through a multidisciplinary 
approach including biochemical, molecular biological and molecular 
modelling methodologies.  
The results of this study have been already published in a peer-reviewed 
journal article [79] and is the result of an international collaboration including 
pharmacology and enzymology experiments (J. Karlsson, M. Svensson and C. 
J. Fowler of University of Umea, Sweden,), chemical synthesis (A. Deplano, 
C. Congiu and V. Onnis of University of Cagliari, Italy), mutant protein 
expression(G. Smaldone and E. Pedone of CNR, Naples, Italy) and 
computational methods (C. M. Morgillo, F. J. Luque, E. Novellino and B. 
Catalanotti of University of Naples Federico II, Italy). 
 
4.2 Pharmacological studies 
The interaction of the enantiomers of Flu-AM1 and Ibu-AM5 with rFAAH 
have been extensively investigated by the group of Prof. Fowler in order to 
determine the main features that characterise the binding mode and to explain 
the importance of the chiral centre in ligand binding. As showed in Fig. 7, the 
experiments of FAAH inhibition in rat brain proved the relevance of the chiral 
centre, since Ibufenac-AM1, which lacks the methyl group on the C-2 carbon 
atom and hence the chiral centre of Ibu-AM5, was a weak inhibitor of rat 
brain FAAH (IC50 = 68 µM).  
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Fig. 7: Inhibition of FAAH by the enantiomers of Ibu-AM5 and Flu-AM1 and by Ibufenac-
AM1. Structures of the compounds are shown in panels A-C: A, Flu-AM1; B, Ibu-AM5; C, 
Ibufenac-AM1. The asterisks show the chiral centres. In panels D-F, the inhibition of 0.5 µM 
[3H]AEA hydrolysis in rat brain homogenates by the compounds is shown. Data are means ± 
SEM (when not enclosed by the symbols), N = 3 for the enantiomers of D, Flu-AM1; E, Ibu-
AM5 and F, racemic Ibu-AM5 and Ibufenac-AM1. 
 
Inhibition experiments evidenced different behaviour between enantiomers of 
Flu-AM1 and Ibu-AM5. (R)-Flu-AM1 was marginally more potent FAAH 
inhibitor than the corresponding (S)-enantiomer (IC50 values of 0.74 and 0.99 
µM, respectively). In contrast, the (R)-enantiomer of Ibu-AM5 was 10-fold 
less potent than the (S)-enantiomer (IC50 values of 5.7 and 0.59 µM, 
respectively). In order to investigate the diversity in the behaviour of the 
enantiomers of Flu-AM1 and Ibu-AM5, molecular modelling was undertaken 
using both docking and MD simulations. 
 
4.3 Validation of the computational protocol 
We have performed a preliminary validation of the whole computational 
protocol, including rigid docking and 50 ns MD simulations by reproducing 
the experimentally determined binding mode of the pyrrolopyridine derivative 
in the crystal structure 3QK5. Among the experimental determined structures 
of the rFAAH inhibitors only carprofen and pyrrolopyridine derivative were 
reported on the PDB server. We have chosen pyrrolopyridine derivative as a 
validation system because of the structural similarity with Flu-AM1 and Ibu-
AM5, while carprofen was  less suitable due to the smaller size (18 heavy 
atoms vs. 25 of Flu-AM1 or 22 of Ibu-AM5), and especially to the negative 
charge, while our compounds are neutral. 
The docking was performed without water, albeit water is likely involved in 
the binding of the pyrrolopyridine derivative. In the validation study, we 
found that the protocol used was able not only to reproduce the ligand 
binding, but also the water position within the active site (Fig. 8).  
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Fig. 8: Comparison of the position of the pyrrolopyridine inhibitor and water molecules in the 
crystal structure 3QK5 (green), in the docking result (yellow), in the best cluster obtained after 
50 ns in the monomer A (cyan) and in the best cluster obtained after 50 ns MD in the monomer 
B (pink). Superimposition was mad on protein backbone. 
 
4.4 Molecular docking of the enantiomers of Flu-AM1 and Ibu-AM5 
The binding mode of the enantiomeric forms of Flu-AM1 and Ibu-AM5 to 
rFAAH enzyme was studied combining docking studies and MD simulations. 
Docking was performed with the software Autodock 4.2 [60], which was 
successful in predicting the binding mode of non-covalent ligands (see 
experimental section §3.1). The ligand poses were ranked considering the 
cluster population and the binding energy. The results showed that the ligand 
bind to a region formed by the ABP channel and the MAC, filling the cavity 
experimentally found for other non-covalent ligands [39, 61]. Two binding 
modes that differ in the orientation of the amide moiety were found (Fig. 9). 
Thus, the amide moiety points towards either the catalytic triad (A-mode) or 
the membrane interacting helices α18-α19 (B-mode). The B-mode was found 
to be the most populated cluster for the two enantiomers, but the scores of A- 
and B-modes were highly similar, thus preventing a firm distinction between 
the ligand orientations (Table 1). 
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Fig. 9: Molecular docking of (S)-Ibu-AM5 and (R)-Flu-AM1 in the competitive site of FAAH. 
Structures of the compounds are shown in relation to their localization in the channels of 
FAAH: A, A-mode of (S)-Ibu-AM5; B, B-mode of (S)-Ibu-AM5; C, A-mode of (R)-Flu-AM1; 
D, B-mode of (R)-Flu-AM1. 
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Table 1: Docking results of the enantiomers of Ibu-AM5 and Flu-AM1 predicted by the 
software Autodock 4.2. a Predicted binding energy of the best pose in the relative cluster 
family. 
 
4.5 Molecular dynamics studies of the enantiomers of Flu-AM1 and 
Ibu-AM5 
To further check structural integrity of two binding modes, the best poses of 
each docking cluster were submitted to 50 ns MD simulation. Two 
independent MD simulations were run on the FAAH dimer, thus enabling 
loading the same docking pose in each monomer, affording four complexes 
for each enantiomeric species.  
As a general trend, the simulations starting from the B-mode remained stable 
along the whole trajectory, whilst the ligand showed significant 
rearrangements when the simulation started from the A-mode. The simulation 
started from the B-mode of (R)-Flu-AM1 remained stable along the whole 
trajectory, as noted in the lack of significant alterations in the positional root-
mean square-deviation (RMSD) for the ligand after an initial stabilization 
(Fig. 10). In contrast, simulations started from the A-mode showed a 
continuous rearrangement and larger fluctuations were observed for the ligand 
(Fig. 10A).  
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Fig. 10: Time evolution (ns) of the RMSD (Å) of the (R)- and (S)-Flu-AM1 enantiomers in the 
MD run starting from A-mode best poses (left), and MD run starting from B-mode best poses 
(right). 
 
The B-mode binding led to a consistent pattern of interactions in the binding 
pocket, whereas the A-mode exhibited less consensus in the interactions 
between ligand and protein. As an additional test, an independent MD 
simulation was run for (R)-Flu-AM1 bound to FAAH dimer starting from the 
B-mode binding, and the results confirmed the structural integrity of the 
ligand arrangement. Indeed, three out of the four complexes converged to a 
common binding mode, which is characterized by the presence of a hydrogen 
bond between the hydroxyl group of Thr488 and the carbonyl unit of the (R)-
enantiomer, as noted in the similar arrangement obtained upon 
superimposition of representative snapshots of MD (Fig. 11). Based on these 
results we have chosen B-mode binding as putative binding for further 
analysis.  
 
Fig. 11: Superposition of representative snapshots taken from the two MD runs of (R)-Flu-AM1 
bound to monomer A (protein in marron, ligand in orange and pink) and monomer B (dark 
cyan). 
 
The ligand (R)-Flu-AM1 is closely packed in the binding site (Fig. 12A), 
forming interactions that are preserved along most of the trajectory. The 
biphenyl moiety fills a hydrophobic cavity, with the distal ring pointing to the 
centre of the anionic hole and forming van der Waals contacts with 
hydrophobic residues lining the ABP channel: Ile491 (at 4.0 Å), Phe381 (at 
4.1 Å) and Leu380 (at 4.0 Å) Ile238 (at 3.8 Å). The fluorinated ring shows 
contacts with the methyl group of Thr488 (at 4.1 Å) and with Phe194 (at 3.7 
Å). The fluorine atom shows a constant distance from aromatic hydrogen of 
the Phe381 (average 3.3 Å). No specific interactions of the methyl group on 
the chiral centre were observed. On the other side, transient hydrogen bonds 
were observed between the pyridine nitrogen and the backbone of Asp403, or, 
alternatively Gly485 (through a water molecule), and between the amide NH 
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unit and the backbone of Leu401. Van der Waals contacts are observed with 
side chains of Met436 and Ile407. The structural integrity of this binding 
mode was maintained upon extension of the trajectory up to 100 ns. 
 
Fig. 12: Representation of (R)-Flu-AM1 (A) and (S)-Flu-AM1 (B) in the competitive binding 
site of the dimeric FAAH as obtained from MD simulations. 
 
The MD trajectories run for (S)-Flu-AM1 led to similar poses in the two 
monomers of FAAH (Fig. 12B). The results showed that the amide bond 
establishes stable hydrogen bonds between the amide NH unit and the 
backbone of Gly485, and between the amide carbonyl with the Thr488 
sidechain. Moreover, the terminal phenyl ring formed van der Waals contacts 
with Leu192, Val495 and Ile491 (at 3.9-4.3 Å), and the fluorinated ring was 
close to Phe381, Leu401, Phe432 and the methyl ring of Thr488. The methyl 
group on the chiral carbon pointed towards Leu404 (at 3.9 Å) and Leu401 (at 
4.5 Å). 
Comparison of (R)- and (S)-Flu-AM1 binding modes is shown in Fig. 12, 
which highlights how the enantiomers were bound in slightly different 
arrangements in the same site located between ABP and MAC channels. 
Nevertheless, the enantiomers showed a very similar pattern of interactions: i) 
the aromatic rings formed a number of van der Waals contacts mainly 
involving aliphatic side chains, ii) the fluorine atom weakly interacted with 
Phe381, and iii) the amidopyridine moiety established hydrogen-bonds with 
Gly485 and Thr488.  
MD simulations of (S)-Ibu-AM5 B-mode converged to similar binding modes 
in the two monomers of FAAH, while no convergence was observed for the 
A-mode. Extension of the MD to 100 ns confirmed the stability of the B-
mode, which remained stable for the last 70 ns of the simulation. (S)-Ibu-AM5 
binds the bottom of the ABP channel and the MAC (Fig. 13A) with the 
pyridine nitrogen fitting the position of the carprofen carboxylic group (PDB 
code 4DO3). The pyridine ring is firmly packed in a hydrophobic residues at 
the gorge of the MAC, interacting with Trp531 (at 3.6 Å), Leu429 (at 3.9 Å), 
and Ile407 (at 4.0 Å from the methyl group). The amide unit of the ligand 
formed hydrogen bonds with the backbone carbonyl of Gly485 and to the 
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Thr488 side chain. The profen moiety is placed in the apolar gorge of the 
ABP with the methyl group on the chiral carbon pointing toward Leu404 (at 
4.2 Å) and Leu401 (at 4.2 Å). The phenyl ring is packed between Phe194 (at 
3.9 Å) and Phe432 (4.2 Å) while the isobutyl group formed van der Waals 
contacts only with Ile238 (at 4.2 Å) and Ile491 (at 3.9 Å). 
 
Fig. 13: Representation of (S)-Ibu-AM5 (A) and (R)-Ibu-AM5 (B) in the competitive binding 
site of the dimeric FAAH as obtained from MD simulations. 
 
Simulations run for (R)-Ibu-AM5 also supported the B-mode binding, leading 
to similar ligand arrangements in the two monomers. Compared to the (S)-
enantiomer, most of the differences arise from the interactions established by 
the amidopyridine moiety, since a hydrogen-bond was formed between the 
carbonyl unit of the amide group and the hydroxyl group of Thr488 and the 
pyridine nitrogen formed a water-mediated contact with Gly485, in addition 
to hydrophobic contacts with Trp531 (at 4.0 Å), Ile407 (at 4.3 Å), and Phe381 
(at 4.0 Å from the methyl). 
 
4.6 Comparison of the binding mode of the enantiomers of Flu-AM1 
and Ibu-AM5 
The comparison of the best representative poses of (R)- and (S)-Flu-AM1 
showed very different binding modes for the two enantiomers, with the (S)-
enantiomer binding deeper in the MAC. The same behaviour was observed 
from the MD simulations of (R)- and (S)-Ibu-AM5 (Fig. 14), suggesting that 
chirality is a main determinant of the binding mode.  
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Fig. 14: Superimposition of the binding mode proposed for (S)-enantiomers (A) and (R)-
enantiomers (B) in the competitive binding pocket of FAAH. 
 
Interestingly, this behaviour seems to be associated to the conformational 
change of Phe432. In the MD trajectories of (S)-enantiomers the Phe432 χ1 
dihedral switched from ~90° to ~180°, allowing the packing of the methyl-
pyridine in a hydrophobic cavity formed by Trp531, Leu429 and Ile407. The 
same Phe432 rotamer (χ1 = ~180°) was found in the crystal structure of 
rFAAH bound to anandamide analogue (PDB code 1MT5), while in the 
binding mode of (R)-enantiomers the Phe432 assume the same conformation 
found in 3QK5 and 4DO3 crystal structures (χ1 = ~90°). Nevertheless, 
enzymatic activity showed that these differences in the binding mode slightly 
affected the activity of Flu-AM1 enantiomers, while it has more remarkable 
effect on the Ibu-AM5 enantiomers. The binding modes of (R)- and (S)-Flu-
AM1, albeit different, resulted comparable, being characterized by a similar 
pattern of hydrophobic interactions and two hydrogen bonds, which is in 
agreement with the similar activities showed by these enantiomers. On the 
contrary, the (S)-Ibu-AM5 binding mode resulted more stable in the light of 
the higher number of hydrogen bonds. 
 
4.7 Comparison with other non-covalent FAAH inhibitors 
These results suggested that Flu-AM1 and Ibu-AM5 bind a region located 
between ABP channel and the entrance of the MAC, overlapping the binding 
of other non-covalent FAAH inhibitors, such as carprofen (PDB code 4DO3) 
and the pyrrolopyridine derivative in the 3QK5 crystal structure. Among the 
two possible binding mode found in docking studies, MD simulations showed 
that only the B-mode shows a relevant interaction with Thr488. The finding 
that (R)-Flu-AM1 is a less potent inhibitor of the FAAHT488A mutated variant 
relative to the wild-type enzyme supported this conclusion, as showed also for 
carprofen inhibition assays (Fig. 15).  
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Fig. 15: Inhibition of rat wild-type and FAAHT488A by (R)-Flu-AM1 (A) and carprofen (B). 
 
The binding mode of these compounds agrees with biochemical experiments, 
since multiple inhibition experiments with carprofen and assays on mutated 
FAAHT488A enzyme suggest that these inhibitors inhibit FAAH in a mutually 
exclusive manner. In fact, comparison between the proposed binding mode 
for (R)-Flu-AM1, (S)-Ibu-AM5, and the binding pose in the crystal structure 
of carprofen and pyrrolopyridine derivative, highlights a similar pattern of 
interaction with FAAH and especially the presence of a hydrogen bond with 
the sidechain of Thr488 (Fig. 16). 
 
Fig. 16: Comparison of the binding modes of (R)-Flu-AM1, (S)-Ibu-AM5, carprofen and the 
pyrrolopyridine derivative. (A) (R)-Flu-AM1 (orange) compared to carprofen (white; PDB ID: 
4DO3); (B) (R)-Flu-AM1 (orange) compared to pyrrolopyridine derivative (green; PDB ID: 
3QK5); (C) (S)-Ibu-AM5 (cyan) compared to carprofen (white); (B) (S)-Ibu-AM5 (cyan) 
compared to pyrrolopyridine derivative (green). Alignment was obtained by superimposition of 
the protein backbone. For sake of clarity only polar Hydrogen were shown. 
 
4.8 Guidelines for drug design  
The above discussion has only considered a single binding site for the 
compounds. However, the kinetic experiments suggested a mixed-type of 
inhibition. This mechanism implies that these compounds should bind to two 
mutually exclusive sites [80]. Therefore, it is difficult to suggest 
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modifications to improve the activity of these compounds dealing with only 
one of the possible sites of action of these inhibitors. In fact, a series of 
substitutions has been attempted on the structure of Ibu-AM5 inhibitor with 
no success in improving the activity against FAAH [25, 26, 58]. As a result of 
the binding mode investigated by computational methods, by two series of 
modification on different branches of the molecule have been simultaneously 
developed: i) modification of different scaffolds from ibuprofen and 
flurbiprofen structure, and ii) modification on the pyridine moiety would 
investigate interactions with FAAH through the polar branch of the 
compound. 
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5. Inhibition of FAAH by 2-(4-((2-
(Trifluoromethyl)Pyridin-4-yl)amino)phenyl)propan 
Amides (TPA) 
5.1 Rational design of TPA derivatives and TPA5 pharmacological 
profile 
The Ibu-am derivatives are characterized by the presence of the isobutyl chain 
of the parent ibuprofen. MD studies on the binding mode of Ibu-AM5 
enantiomers, showed that in both (S)- and (R)-Ibu-AM5 the isobutyl chain 
fills a wide pocket within the ABP channel, allowing two main populated and 
opposite positions of the isobutyl chains (Fig. 17).  
 
Fig. 17: Isobutyl moiety flexibility during MD of Ibu-AM5. A) Two subsequent snapshots of 
the MD run of (S)-Ibu-AM5. The ligand is shown in green and cyan sticks, while the 
surrounding residues are labeled and shown in cyan sticks. B) Time evolution of the dihedral 
angle of isobutyl moiety during MD of the ligand in monomer A (blue) and in monomer B 
(orange). 
 
With the aim to modulate the lipophilicity of the compounds and achieve a 
tighter binding, we explored the possibility to substitute the isobutyl group of 
Ibu-AM5 with 4-((2-(Trifluoromethyl)Pyridin-4-yl)amino group, obtaining a 
new series of profen derivatives synthesized by the group of Prof V. Onnis 
and tested by the group of Prof C. J. Fowler: 2-(4-((2-
(Trifluoromethyl)Pyridin-4-yl)amino)phenyl)propanAmides (TPA) (Fig. 18). 
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Fig. 18: Design strategy starting from Ibu-AM5 to TPA. 
 
Replacing iso-butyl group of Ibu-AM5 with a trifluoromethylpyridinylamino 
moiety led to TPA5, which maintains the FAAH inhibitory activity (IC50 
value = 0.59 µM). The kinetics of TPA5 binding was also examined to gain 
insight into the mechanism of action of this novel class of FAAH inhibitors. 
TPA5 resulted a competitive inhibitor (Fig. 19, B1), showing little 
dependency upon preincubation time, which suggests a reversible inhibition 
(Fig. 19, A1). 
 
Fig. 19: Mode of inhibition of rat brain FAAH by TPA5. Panel A: homogenates were 
preincubated with the compounds for the times shown prior to addition of 0.5 μM [3H]AEA 
and assay for FAAH activity (means and s.e.m., n=3-4) Panel B: AEA hydrolysis at the 
substrate and inhibitor concentrations shown (means and s.e.m, n=3). 
 
Taking into account the competitive mechanism of TPA5, we studied its 
binding mode by using the docking and MD protocol previously described for 
enantiomers of Flu-AM1 and Ibu-AM5 (see §4.3). Given that (S)-Ibu-AM5 is 
10-fold more potent than (R)-Ibu-AM5 as inhibitor of FAAH, while the (S)-
Flu-AM1 enantiomer is almost as equipotent as the more active (R)-
enantiomer, we used the (S)-enantiomer for computational studies on the TPA 
derivatives. 
 
5.2 Molecular docking of TPA5 
Docking was performed in the competitive site of the enzyme, adopting the 
same approach used for the enantiomers of Flu-AM1 and Ibu-AM5 (see §4.4). 
The results showed that the ligand binds a region formed by the ABP channel 
in proximity to the catalytic triad, but adopting up to four different 
arrangements (Table 2). 
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Table 2: Docking results for TPA5 predicted by Autodock 4.2 
 
The binding modes differed in the orientation and positioning of the molecule 
along the channels, having the amide moiety pointing towards the cytosolic 
port (A1-mode), the catalytic triad (A2-mode),  the membrane access channel 
(B1-mode) or the membrane interacting helices α18-α19 (B2-mode) (Fig. 20). 
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Fig. 20: Molecular docking of TPA5 in the competitive site of FAAH. Structures of the 
compounds are shown in relation to their localization in the channels of FAAH: A, A1-mode; 
B, A2-mode; C, B1-mode; D, B2-mode. 
 
5.3 Molecular dynamics and free energies calculation of TPA5 in the 
competitive site 
The A1-mode was found to be the most populated and energetically favoured 
cluster for TPA5, but we preserved also other binding modes for MD 
simulation analyses, due to their similarity to the binding modes found for the 
enantiomers of Ibu-AM5 and Flu-AM1. 
The best pose for each binding mode was submitted to 100 ns MD 
simulations. Compared to the MD studies on the enantiomers of Ibu-AM5 and 
Flu-AM1, we have doubled the length of the simulation time to perform more 
exhaustive analysis on the stability of the four binding modes found for 
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TPA5. The calculations were performed on the dimeric form of the enzyme 
loading the docking pose on both monomers, while analyses were performed 
on the single monomers. 
The A1-mode was found to be very stable during 100 ns of MD, as showed in 
the RMSD plot of the ligand (Fig. 21A), and the convergence to the same 
binding mode in the two monomers (Fig. 21B). 
 
Fig. 21: MD refinement of TPA5 A1-mode. A: RMSD plot during 100 ns of MD refinement of 
the ligand in monomer A (black) and monomer B (red). B: superimposition of the competitive 
binding site refinement at the end of 100 ns of MD in monomer A (grey) and monomer B 
(indigo). 
 
The MD refinement of A1-mode led to a tight packed binding between the 
catalytic triad and the ABP channel, showing the high stability of the TPA5 
conformation adopted during the trajectory. It is worth noting that this binding 
mode influences the arrangements of the residues in the MAC channel, 
leading to the closure of the entrance gate for the FAAH substrates.  
The A2-mode showed little differences in the binding of TPA5 in the two 
monomers. As observed in the RMSD plot, the ligand in monomer B showed 
a net conformational change after 75 ns, corresponding to the switch of the 
torsional of the trifluoromethyl-pyridin moiety (Fig. 22A), while the other 
parts of the ligand bind in a stable manner to the ABP channel (Fig. 22B). 
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Fig. 22: MD refinement of TPA5 A2-mode. A: RMSD plot during 100 ns of MD refinement of 
the ligand in monomer A (black) and monomer B (red). B: superimposition of the competitive 
binding site refinement at the end of 100 ns of MD in monomer A (brown) and monomer B 
(green). 
 
The B1-mode showed a quick rearrangement of TPA5, reflected in the RMSD 
plot of the ligand in the monomers A and B, which show a firm fluctuation in 
the initial phase of MD refinement (Fig. 23A). Cluster analysis of the ligand 
in the two monomers led to a similar binding mode with different orientations 
of the methyl-pyridine moiety in the MAC channel (Fig. 23B). 
 
Fig. 23: MD refinement of TPA5 A1-mode. A: RMSD plot during 100 ns of MD refinement of 
the ligand in monomer A (black) and monomer B (red). B: superimposition of the competitive 
binding site refinement at the end of 100 ns of MD in monomer A (cyan) and monomer B 
(magenta). 
 
The B2-mode showed very distinct binding modes in the two monomers. As 
seen in the RMSD plot, the ligand in the monomer A showed large fluctuation 
and binds a region between ABP and MAC channels (Fig. 24A). Moreover, 
the different positioning of the ligand in the two monomers influenced the 
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arrangement of the surrounding residues, as seen for α18 and α19 helices (Fig. 
24B). 
 
Fig. 24: MD refinement of TPA5 A1-mode. A: RMSD plot during 100 ns of MD refinement of 
the ligand in monomer A (black) and monomer B (red). B: superimposition of the competitive 
binding site refinement at the end of 100 ns of MD in monomer A (yellow) and monomer B 
(pink). 
 
To discriminate among the conformational ensembles sampled for each 
binding mode in the MD refinement, the binding free energies were 
determined using three approaches: Molecular Mechanics Generalized Born 
Surface Area (MM/GBSA) and Molecular Mechanics Poisson Boltzmann 
Surface Area (MM/PBSA) and Solvated Interaction Energy (SIE) (see 
Experimental Section for details of the underlying formalisms). As said 
before, only A1-mode was found to converge to the same binding mode in the 
two monomers A and B, while other bindings led to distinct conformational 
ensembles for each monomer (Fig. 21B-24B). Both MMPBSA, MMGBSA 
and SIE calculations supported the preference for the A1-binding mode of 
TPA5 (Table 3). 
 
Table 3: Free energy calculation of the representative binding modes refined through MD runs 
of 100 ns. In case of non-convergent binding mode, the evaluation of free energies of binding 
are reported for the best cluster in the monomer A (a0) and B (b0). MMPBSA, MMGBSA and 
SIE values are in kcal/mol. 
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Docking scores, MD convergence and estimation of binding affinity strongly 
indicated the A1-binding mode as the preferred pose. Nevertheless, taking 
into account that very similar compounds, such as Flu-AM1 and Ibu-AM5, 
showed binding modes comparable to the B2-mode, we opted for a more 
robust method to further assess the preference of the A1-binding mode for 
TPA5. Indeed, hybrid quantum mechanical molecular mechanics (QM/MM) 
calculations were submitted for each representative binding mode. Being 
QM/MM computationally more expensive method, we restricted these 
calculations to the residues surrounding a subset of 15 Å from the centre of 
mass of the binding modes refined by MD to avoid any loss of the interactions 
that might influence the binding affinities. The QM/MM results confirmed the 
previous free binding energies calculations (Table 4). 
 
Table 4: QM/MM results on the binding modes for TPA5. QM/MM scores were obtained on 
the dry complexes, therefore solvation energies from GBSA and PBSA calculations were added 
to obtain final values of binding energies. 
 
The analysis of the more representative snapshot of the A1-mode (Fig. 25) 
showed that TPA5 binds through a series of hydrogen bonds and prevalently 
by hydrophobic interactions with the apolar gorge of ABP (Fig. 25). In 
particular, the methyl-pyridine moiety is in the proximity of the catalytic triad, 
tightly packed by apolar interactions with residues Met191, Leu192, Ile228, 
Val270 and Leu278 (Fig. 25B). The carbonyl oxygen of the amide resides 
permanently near the anionic hole formed by the main chains of residues 
Ile238, Gly239, Gly240 and Ser241, while the NH group forms a stable 
hydrogen bond with the backbone of Met191. The interactions of the amide 
group and of the methyl-pyridine ring required the adoption of a specific 
conformation, which seems therefore to be a key requisite for FAAH 
inhibition for this class of compounds. Further apolar interactions of the 
aromatic groups with residues along the channel, and a water-bridged H-bond 
of aromatic and the backbone of Leu192 contribute to stabilize the binding 
(Fig. 25A).  
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Fig. 25: A1-mode of TPA5 refined after 100 ns of MD. A) Hydrogen bond of TPA5 (cyan, in 
sticks) in A1-mode. B) Apolar interaction in the binding pocket of the FAAH. The ligand TPA5 
is represented in cyan by van der Waals spheres. 
 
5.4 Structure Activity Relationships of TPA derivatives 
A series of substitutions were designed on the TPA5 structure with the aim to 
explore the structure-activity relationships of the ligand in the binding pocket. 
Substitutions on the methyl-pyridine amide moiety, which allows more 
flexibility to this region, as the introduction of a methylene linker (TPA8, 
TPA9), as well as the linker extension through an additional amide moiety 
(TPA10), caused a decrease in activity (Table 5). According to the selected 
binding mode A1, these modifications avoid the positioning of the methyl-
pyridine ring in the pocket defined by residues Met191, Leu192, Ile228, 
Val270 and Leu278. 
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Table 5: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compounds TPA5, TPA8-10. 
 
Similarly, we can explain the drop of activity showed by derivatives bearing 
different position of the methyl group on the pyridine ring (TPA11, TPA12) 
(Table 6) or lacking the methyl in position 5 on the methyl-pyridine ring, such 
as TPA13 (Table 6), TPA14 and TPA15 (Table 7) and in a lesser extend 
TPA18 (Table 7). The methyl group plays a key role in the conformational 
behaviour of TPA5, determining the relative positioning of the methyl-
pyridine ring with respect to the amide bond, besides the specific apolar 
interactions formed by the methyl group with side chains of Val270 and 
Leu192.   
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Table 6: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compounds TPA5, TPA11-13. 
 
Moreover, the position of nitrogen on the methyl-pyridine ring is not 
implicated in direct polar interaction in the binding mode presented for TPA5. 
In fact, the toluene analogue TPA16 showed similar activity in respect to 
TPA5, while analogues with different position of the nitrogen in the pyridine 
ring showed a decrease in activity (TPA14, TPA15, TPA17, TPA18). These 
data confirm the greater importance of the presence of the 3-methyl pyridine 
substituent than nitrogen atom position. Finally, the introduction of a larger 
and more lipophilic ring, like the 8-aminoquinoline group in TPA19, caused a 
reduction in activity (Table 7), indicating that there is no space to 
accommodate larger groups. 
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Table 7: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compounds TPA14-19. 
 
The inclusion or replacement of the methyl group in the pyridine ring by 
halogens (TPA24-27) increased the inhibitory activity. In particular, 
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substitution by chloride (TPA27) led to a 10-fold enhancement in inhibitory 
potency (Table 8). This group of derivatives presented relative small changes 
in structure compared to the lead TPA5. Hence, we focused our studies in 
understanding why the substitution of the methyl (TPA5) by chlorine 
(TPA27) increased the inhibitory activity.  
 
Table 8: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compounds TPA5, TPA24-27. 
 
The binding of TPA27 was further analysed by means of inhibition kinetics 
experiments in order to define the mechanism of action of this derivative. The 
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results showed that TPA27 (Fig. 26B), unlike TPA5, behaves as non-
competitive inhibitor with Ki and alpha values of 0.28 µM and 1.03, 
respectively. Since for pure non-competitive inhibitors alpha is expected to be 
1, these results demonstrated that TPA27 is essentially non-competitive in its 
action. Moreover, preincubation and dilution experiments also demonstrated 
the reversibility of its action (Fig 26A).  
 
Fig. 26: Mode of inhibition of rat brain FAAH by TPA27. Panel A: homogenates were 
preincubated with the compounds for the times shown prior to addition of 0.5 μM [3H]AEA 
and assay for FAAH activity (means and s.e.m., n=3-4). Panel B: AEA hydrolysis at the 
substrate and inhibitor concentrations shown (means and s.e.m, n=3). 
 
Taken into account these data, it may be assumed that TPA5 and TPA27 act 
as FAAH inhibitors interacting with two different binding sites in the enzyme. 
Therefore, kinetic experiments highlighted how small substitutions in the 
compounds belonging to the series of TPA derivatives, should dramatically 
affect the inhibition mechanism and binding preferences of these inhibitors. In 
light of such considerations, caution should be taken in order to derive the 
structure-activity relationships, since apparently minor structural 
modifications could influence not only the binding mode, but also the 
inhibition mechanism. 
In order to analyse the molecular basis of these subtle effects, thermodynamic 
integration (TI) calculations [81] were used to calculate the differences in 
binding free energy between TPA5 and TPA27. TI is best used in situations 
where small changes in structure correlate with relatively substantial changes 
in the binding affinity. Therefore, TI was used to specifically address to the 
role of substitution of the methyl group on the pyridine ring in TPA5 with the 
chlorine group in TPA27, performing the alchemical mutation from TPA5 to 
TPA27 in the selected binding mode of TPA5 (A1-mode). The calculation 
yielded a free energy difference of 0.3 kcal/mol, thus indicating a slightly 
higher affinity of TPA5 with respect to TPA27, whereas the experimental data 
indicated that TPA27 was 10-fold more potent inhibitor than TPA5. In our 
view, this is indirect evidence that TPA27 could not bind the enzyme 
mimicking the competitive binding mode of TPA5, as the estimated change in 
binding affinity is opposite to the experimental evidence. Indeed, this finding 
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would agree with the experimental finding that TPA27 follows essentially a 
non-competitive inhibition mechanism. 
 
5.5 Comparison with other FAAH inhibitors 
Our results suggest that TPA5 binds a region located between the catalytic 
triad and the MAC, overlapping the binding of the anandamide analogue 
MAFP (PDB code 1MT5) and consequently, overlapping the binding mode of 
the series of α-ketoheterocycle covalent FAAH inhibitors [41, 42, 45, 46]. In 
fact, the superimposition of the X-ray structure of MAFP with TPA5 
highlights how the ligand adopts a conformation to bind the FAAH that 
matches well the structure of MAFP, although this latter compounds binds 
even deeper in the MAC (Fig. 27A). A similar behaviour is observed by the 
superimposition with three different compounds of the series of α-
ketoheterocycle covalent FAAH (Fig. 27B-D). In particular, the carbonyl 
moiety of the two compounds fills the same position, pointing towards the 
anionic hole, while the nitrogen on the pyridine ring of TPA5 overlaps the 
nitrogen in the oxazole moiety (Fig. 27D). 
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Fig. 27: Superimposition of the binding mode of TPA5 (grey sticks) with X-ray structure of 
anandamide analogue MAFP (A: pdb code 1MT5, yellow sticks), and series of α-
ketoheterocycle covalent FAAH inhibitors (B: pdb code 3K83, aquamarine sticks; C: pdb code 
3PR0, light green sticks; D: pdb code 2WJ2, tan sticks). Catalytic triad and anionic hole are 
represented in sticks, helices α18-α19 are represented in orange cartoon. 
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6. Structural investigation of the allosteric site in FAAH 
 
The above discussion has only considered a single binding site for the 
compounds. However, the kinetic experiments performed by Prof. Fowler and 
co-workers at the University of Umea (Sweden) suggested a variety of 
mechanisms underlying the inhibitory activity (Table 9).  
 
Table 9: Comparison of potencies (µM) and modes of inhibition for key compounds identified 
in this thesis: species dependency between rat and mouse FAAH. IC50 values refer to the 
inhibition of the hydrolysis of 0.5 µM [3H]AEA by rat or mouse brain homogenates, as 
appropriate.  Ki and α values were obtained using the enzyme kinetics inhibition curve fitting 
algorithms available in the GraphPad Prism programme. Under settings “weightings” and 
“replicates” in the programme, “no weighting” and “only consider the mean Y value of each 
point” were used. Only data using ≥8 substrate concentrations has been included here. 
Comparisons of different models: competitive, non-competitive, mixed-type inhibition were 
undertaken and the best fit was chosen by Akaike’s informative criteria.  aThese values of α are 
by definition for the competitive or non-competitive inhibition. 
 
In the rat brain homogenates, Ibu-AM14 [26] and TPA5 inhibited [3H]AEA 
hydrolysis in a competitive manner, whereas TPA27 was a non-competitive 
inhibitor. Ibu-AM5 and Flu-AM1 enantiomers were mixed-type inhibitors of 
rat brain [3H]AEA hydrolysis. In contrast, in mouse brain homogenates, both 
TPA5 and TPA27 were mixed-type inhibitors, whereas (R)-Flu-AM1 was 
competitive in nature. A mixed-type inhibition has been associated to an 
allosteric mode of inhibition, or to a non-competitive binding to the active site 
[82]. As an example of non-competitive binding to the active site, NSAIDs 
such as flurbiprofen (but not ibuprofen) interact with COX in a two-step 
reaction whereby an initial competitive interaction is followed by a slower 
tight-binding or even irreversible inhibition. However, in these cases, the time 
dependency is very marked, occurring over minutes [83].  In the present case, 
there was some apparent time-dependency with (R)-Flu-AM1 (Fig. 28A), but 
it was very slow, and we have previously not seen such time-dependency with 
racemic Flu-AM1, despite its mixed-type mode of inhibition [25]. Moreover, 
dilution experiments demonstrated the full reversibility of (R)-Flu-AM1 (Fig. 
28C).  
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Fig. 28: Time-dependency and reversibility of the inhibition of rat brain FAAH by (R)-Flu-
AM1. Panels A and B show the time-dependencies of (R)-Flu-AM1 and URB597, respectively. 
The data are means ± SEM, N = 3. In Panel C, homogenates (at 20-fold normal strength) were 
preincubated with either vehicle, 2, 4 or 6 μM (R)-Flu-AM1 for 60 min. Aliquots were then 
diluted 20-fold and assayed for FAAH activity. These are shown as 2→0.1, 4→0.2 and 6→0.3. 
Concomitantly, (R)-Flu-AM1 was added to vehicle-preincubated aliquots to give 
concentrations of 0.1, 0.2 and 0.3 μM (representing free concentrations after a 20- fold 
dilution), 2, 4 and 6 μM final concentrations. The panel shows the data as percentage of 
corresponding control (means ± SEM, N = 3).  For a fully reversible compound, the inhibition 
seen in the yellow bars (i.e. following the dilution) should be lower than in the purple bars (the 
inhibition seen at the undiluted concentrations) but equal to the green bars (the free 
concentrations after the dilution). 
 
We thus do not favour this mechanism as an explanation for our data. A 
simpler mechanism for a fully reversible linear-mixed type inhibition of the 
amidic profen derivatives may involve binding to two mutually exclusive sites 
[80]. Such a model would be consistent with the data, and would represent a 
particular case of the mixed inhibition model shown in Fig. 29. 
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Fig. 29: Scheme of mixed-type inhibition 
 
Indeed, we could speculate that mixed inhibition arise from comparable 
affinities toward the two binding sites, with weak preference for the 
competitive site (determined by α; Table 9). Competitive inhibitors such as 
TPA5 would bind the non-competitive site with very little affinity, if any. 
Finally, the non-competitive mechanism of TPA27 could be explained by a 
marked binding preference for the non-competitive binding site, so that the 
binding to FAAH is not affected by the presence of the substrate. Structural 
differences in the competitive and non-competitive binding sites for rat and 
mouse FAAH could then give rise to the different observed modes of 
inhibition, and the lower potencies of the compounds, generally by one order 
of magnitude, in mouse FAAH compared to the rat enzyme. Similarly, small 
differences in structure would drive the affinity toward the two binding sites 
giving rise to different mode of inhibition. 
In light of such considerations, we were prompted to search of an allosteric 
binding site for these compounds. 
 
6.1 Pocket detection 
A first step to harness the regulatory potential and versatility of allosteric sites 
would be to identify their presence and location. A sequence-based prediction 
approach proposes to use a multiple sequence alignment to identify networks 
of co-evolving residues in a protein family.  Based solely on sequence, it 
would be very hard to predict the location of allosteric sites as it has been 
done by homology on active sites [84, 85], because the evolutionary pressure 
for sequence conservation on allosteric sites is generally much lower and 
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harder to detect, if at all present [86, 87]. Instead, a structure-based prediction 
approach identifies and ranks the druggable pockets in the 3D structure of the 
protein. 
In order to detect an allosteric site on the FAAH enzyme, we have used 
fpocket webserver [88] to analyse the overall FAAH cavities in the 3D 
structure of rFAAH and mFAAH. The main goal of this approach is to 
discover druggable binding sites on FAAH able to be modulated by small-
molecule interactions. We focused the analysis on the 10 best pockets scored 
by fpocket and compared the amino acidic sequence involved in the 
composition of the pockets between mouse and rat structures, with the aim to 
compare whether differences in the protein sequence may lead to different 
cavities in the enzyme (Table 10).  
 
 
Table 10: Best 10 pockets ranked by fpocket webserver. Predictions were performed on FAAH 
dimer, thus the residue that define each pocket are specified by monomer in parenthesis. 
Residues are defined for the rat FAAH structure and the corresponding mutants are reported in 
mouse FAAH.  
 
Analysis of the results revealed that the best three pockets were internal 
cavities, while pockets from 4 to 9 were located on the surface exposed to the 
solvent (Fig. 30).  
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Fig. 30: Results of the pockets screened by fpocket webserver. Rat FAAH are represented by 
cyan cartoon with helices α18-α19 highlighted in orange. Residues of the catalytic triad are 
represented by magenta sticks. Pockets are represented in spheres by colour code reported in 
the table below. Three best results of fpocket are highlighted on the top of the figure.  
 
Moreover, we also found some asymmetric differences between monomers A 
and B of rFAAH. In fact, among the best ranked pockets, pocket 1 in 
monomer A (black spheres) is larger than the corresponding pocket in 
monomer B (pocket 3, green spheres), since pocket 1 includes residues 
classified as an independent pocket in monomer B (pocket 10, grey). 
Therefore, we found two druggable internal cavities in FAAH: i) (in black and 
green) the first cavity is located between the catalytic triad and the membrane 
interacting helices α18-α19 and represents the pocket occupied by the 
substrate and hence is considered as the competitive pocket, and ii) (in blue) a 
second cavity is located in the cytosolic port that connects the catalytic triad 
to the cytosol, allowing the release of the ethanolamine produced by the 
hydrolysis of anandamide and the access of water needed to release 
arachidonic acid.  
To further check the capability of all detected pockets to bind amide profen 
derivatives, we performed docking with Autodock4.2 on a box including all 
the pockets found with the previous pocket analysis. Docking was performed 
on Ibu-AM5, which is the smallest ligand that could bind an allosteric site. 
We performed 200 iterations with the aim to improve the search for potential 
binding sites enlarging the sampling. 
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Docking solutions were located between the pockets coloured in blue, green 
and grey as determined by fpocket (Fig. 31), excluding the implication of the 
external cavities. 
 
Fig. 31: Docking results on the box (blue) that includes the pockets predicted by fpocket (in 
transparent spheres with the colour code used in the Table 12). Rat FAAH are represented by 
cartoon, showing helices α18-α19 in orange cartoon and catalytic triad in magenta sticks. 
Ligand poses of the docking are displayed in sticks and the putative box for the allosteric site 
are represented in red. Results are listed in the table at the bottom of the figure. AD scores are 
expressed in kcal/mol. 
 
The docking prediction has reported all the solutions investigated in the 
competitive site for the binding of the enantiomers of Ibu-AM5, Flu-AM1 and 
TPA5. These solutions could be included in the green and grey pockets. 
Nonetheless, a high percentage of solutions fill the blue pocket. Taking into 
account these results, we have defined a box located between the catalytic 
triad and the interface between monomers and we used this box to examine 
the binding of mixed-type and non-competitive inhibitors in this pocket (red 
box in Fig. 31).  
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6.2 Molecular docking in the allosteric pocket 
The binding mode of the inhibitors (S)-Ibu-AM5, (R)-Flu-AM1 and TPA27 to 
the rFAAH allosteric site was studied combining molecular docking and MD 
simulations.  
The ligands bind a region between catalytic triad and CP. Two binding modes 
that differ in the orientation of the amide moiety were found (Fig. 32). Thus, 
the amide moiety may point towards either the catalytic triad (A-mode) or the 
interface between FAAH monomers (B-mode). 
 
Fig. 32: Molecular docking of (S)-Ibu-AM5 (green), (R)-Flu-AM1 (pink) and TPA27 (blue) in 
the allosteric pocket found by fpocket. A: A-mode; B: B-mode. FAAH monomers are 
represented in cartoons (green for monomer A and brown for monomer B). Internal cavities are 
represented by surface and catalytic triad is represented by magenta sticks.  
 
The A-mode achieved better scores for all the ligands and was found to be the 
most populated cluster (Table 11). The A-binding mode yielded very similar 
results for (S)-Ibu-AM5, (R)-Flu-AM1 and TPA27, having the pyridine ring 
in the same conformation, whilst few differences in the positioning of 
pyridine ring were found for the B-binding mode. Docking results were also 
re-scored using MM/GBSA calculations that confirmed that the two modes 
slightly differ in energy, confirming the preference for the A mode for Ibu-
AM5 and Flu-AM1, but indicating a preference for the B-mode for TPA27. 
However, keeping in mind the uncertainty of MM/GBSA calculations, caution 
must be taken to not overemphasize the significance of the reduced 
differences in the predicted binding affinities. 
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Table 11: Docking results in the allosteric pocket for (S)-Ibu-AM5, (R)-Flu-AM1 and TPA27. 
AD score and MM/GBSA values are expressed in kcal/mol. 
 
6.3 Molecular dynamics studies in the allosteric pocket 
To further check the structural integrity of two binding modes, the best poses 
of each docking cluster were submitted to 100 ns of all atom MD simulation. 
MD simulations were run on the FAAH dimer, loading the same docking pose 
in each monomer, while the analysis of MD simulations was carried out in the 
single monomer.  
6.3.1 Ibu-AM5 MD simulations 
The MD simulation starting from the A-mode of Ibu-AM5 showed 
differences about the position of the ligand within the CP in the two 
monomers, as a consequence of the different fluctuation of the ligand in the 
first 40 ns of MD simulation, as showed by the RMSD plot (Fig. 33).  
 
Fig. 33: MD refinement of Ibu-AM5 A-mode in the allosteric pocket. A: RMSD plot during 
100 ns of MD refinement of the ligand in monomer A (orange) and monomer B (green), 
referred to the docking. B: superimposition of the monomers after 100 ns of MD refining: 
allosteric pocket is represented as internal surface (grey), ligand in monomer A is orange and in 
monomer B is green. The brown helix represents the other monomer. 
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The ligand in monomer A, after an initial equilibration, formed two stable 
hydrogen bonds between the carbonyl group of the amide moiety and the 
main chains of Gly272 and Gln273, and the hydrogen bond between the 
nitrogen atom of the pyridine ring and the sidechain of Gln273 (Fig. 34). On 
the contrary, the simulation in monomer B did not show specific H-bonds 
between ligand and enzyme, while the isobutyl moiety was located in the 
aqueous environment at the tip of the CP.  
 
Fig. 34: A-mode of Ibu-AM5 refined after 100 ns of MD. Residues of monomer A are coloured 
in green and residues of monomer B are coloured in brown. A) Hydrogen bond of Ibu-AM5 
(orange, in sticks) in A-mode. Water molecule at the interface between FAAH monomers are 
displayed as sticks. B) Apolar interaction in the binding pocket of the FAAH. The ligand Ibu-
AM5 is represented in orange by van der Waals spheres. 
 
In addition, MD simulations starting from the B-mode showed different 
results in the two monomers. In fact, as showed in the RMSD plot, the ligands 
in the two monomers led to different ensembles after 50 ns, showing an 
increase of the RMSD for the ligand in monomer A (Fig. 35).  
 
Fig. 35: MD refinement of Ibu-AM5 B-mode in the allosteric pocket. A: RMSD plot during 
150 ns of MD refinement of the ligand in monomer A (magenta) and monomer B (yellow), 
referred to the docking. B: superimposition of the monomers after 150 ns of MD refining: 
allosteric pocket is represented as internal surface (grey), ligand in monomer A is magenta and 
in monomer B is yellow. The brown helix represents the other monomer. 
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In particular, the RMSD relative to the ligand in monomer A showed large 
fluctuations in the first 50 ns of simulations and highlights a slow 
equilibration of the ligand. Visual inspection of the MD trajectory revealed 
that, during this long equilibration, the ligand, starting from a position very 
similar to that found in the monomer B, progressively enter within the CP, 
until the isobutyl moiety of Ibu-AM5 fills in a hydrophobic cavity formed by 
Phe381, Phe388, Leu380, Leu192 and Leu404. This binding mode is further 
stabilised by the formation of hydrogen bonds between the nitrogen on the 
pyridine ring and the main chains of Cys269 and Val270. In addition, Tyr271 
formed stacking interaction with the pyridine ring, while the methyl group on 
the pyridine ring was packed between Met191, Leu278 and Leu154 (Fig. 36).  
 
Fig. 36: B-mode of Ibu-AM5 in monomer A refined after 150 ns of MD. Residues of monomer 
A are coloured in green and residues of monomer B are coloured in brown. A) Hydrogen bond 
of Ibu-AM5 (magenta, in sticks) in B-mode. Water molecule at the interface between FAAH 
monomers are displayed by sticks. B) Apolar interaction in the binding pocket of the FAAH. 
 
The binding of the ligand in monomer B showed different behaviour, with 
fewer fluctuations in the initial phase of MD simulation. The isobutyl moiety 
interacts with Leu192, Phe388, Leu380 and Ile238, while the carbonyl of the 
amide moiety forms hydrogen bonds through water molecule with the main 
chains of Cys269 and Val270. Moreover, this conformation is further 
stabilised by hydrogen bonds of the amide moiety with the backbone of 
Lys263, and between the nitrogen on the pyridine group and the backbone of 
Leu266 (Fig. 37). 
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Fig. 37: B-mode of Ibu-AM5 in monomer B refined after 150 ns of MD. Residues of monomer 
B are coloured in brown and residues of monomer A are coloured in green. A) Hydrogen bond 
of Ibu-AM5 (yellow, in sticks) in B-mode. Water molecule at the interface between FAAH 
monomers are displayed by sticks.  B) Apolar interaction in the binding pocket of the FAAH. 
 
Superimposition of the bindings in the two monomers highlights some 
differences in the enzyme structure that lead to different ensembles (Fig. 38): 
i) the displacement of the loop 376-399 leads to the rearrangement of Leu380 
and Phe381, that accommodate the isobutyl moiety deeper in an hydrophobic 
cavity formed by Phe381, Phe388, Leu380, Leu192 and Leu404; ii) the direct 
interactions of the pyridine nitrogen with the anionic hole formed by main 
chains of Cys269 and Val270, that helped the inhibitor to adopt the 
conformation able to gain the entrance in the hydrophobic pocket; and iii) the 
orientation of the methyl group on the pyridine ring that permanently interacts 
with Met191 and Leu156.  
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Fig. 38: Superimposition of the binding mode B of Ibu-AM5 in the allosteric pocket. Catalytic 
triad are represented in magenta sticks. Ibu-AM5 (magenta in monomer A, yellow in monomer 
B) and surrounding residues are (green in monomer A, brown in monomer B) represented by 
stick. 
 
6.3.2 Flu-AM1 MD simulations 
The MD simulations starting from the A-binding mode of Flu-AM1 showed 
slightly different conformations of the ligand in the two monomers. As shown 
in the RMSD plot, the ligand in monomer A undergoes to major 
modifications, resulting in a different occupation of the CP by biphenyl and 
methyl on C-2 moieties (Fig. 39), while the ligand in monomer B showed a 
very stable binding mode along the 100 ns trajectory. 
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Fig. 39: MD refinement of Flu-AM1 A-mode in the allosteric pocket. A: RMSD plot during 
100 ns of MD refinement of the ligand in monomer A (violet) and monomer B (green), referred 
to the docking. B: superimposition of the monomers after 100 ns of MD refining: allosteric 
pocket is represented as internal surface (grey), ligand in monomer A is violet and in monomer 
B is green. The brown helix represents the other monomer. 
 
The stability of the binding after 100 ns MD of the ligand in monomer B 
prompted us to select this binding mode as the most representative pose of the 
A-mode. Analysis of the binding mode showed similar array of interactions of 
the A-mode of Ibu-AM5, with the biphenyl moiety partially facing to the 
aqueous environment, establishing few hydrophobic contacts with Met453 
and Leu278, while the polar portion of the inhibitor is stabilised by hydrogen 
bonds with Gln273 backbone and sidechain (Fig. 40).  Finally, the methyl-
pyridine ring established hydrophobic contacts with Ile238, Leu380 and 
Val270. 
 
Fig. 40: A-mode of Flu-AM1 in monomer B refined after 100 ns of MD. Interacting residues 
are showed in sticks (brown, monomer B; green, monomer A). A) Hydrogen bond of Flu-AM1 
(green, in sticks) in B-mode. B) Apolar interaction in the binding pocket of the FAAH. The 
ligand Flu-AM1 is represented in green by van der Waals spheres. 
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The MD simulation of the B-binding mode of Flu-AM1 showed the same 
conformation of the ligand in the two monomers, but a different positioning 
within the pocket. The RMSD plot showed some fluctuations, in particular in 
the last 15 ns of MD (Fig. 41). Analysis of the trajectory revealed that they 
were due to the transient rotation of the methyl-pyridine ring.  
 
Fig. 41: MD refinement of Flu-AM1 B-mode in the allosteric pocket. A: RMSD plot during 
100 ns of MD refinement of the ligand in monomer A (violet) and monomer B (blue), referred 
to the docking. B: superimposition of the monomers after 100 ns of MD refining: allosteric 
pocket is represented as internal surface (grey), ligand in monomer A is violet and in monomer 
B is blue. The brown helix represents the other monomer. 
 
The analysis of the binding modes found in the two monomers highlighted a 
similar pattern of interactions. Here we describe the binding in monomer B, 
since it is characterized by a better stability according to the RMSD plot in 
Fig. 41 The B-mode of Flu-AM1 showed the biphenyl moiety filling a 
hydrophobic pocket formed by Leu192, Ile238, Val276, Leu278, Leu380 and 
Phe388. Furthermore, the carbonyl of the amide moiety forms hydrogen bond 
with the backbone of Gly272, the methyl-pyridine ring is stabilised through 
stacking interactions with His449 and Tyr271, but the methyl group is 
surrounded by water molecules (Fig. 42). 
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Fig. 42: A-mode of Flu-AM1 in monomer B refined after 100 ns of MD. Interacting residues 
are showed in sticks (brown, monomer B; green, monomer A). A) Hydrogen bond of Flu-AM1 
(blue, in sticks) in B-mode. Water molecule at the interface between FAAH monomers are 
displayed by sticks.  B) Apolar interaction in the binding pocket of the FAAH.  
 
6.3.3 TPA27 MD simulations 
The MD simulations of the A-binding mode of TPA27 yielded similar results 
in the two monomers after 100 ns MD refinement, showing slightly difference 
in the orientation of the chloropyridine ring and trifluoropyridine moieties 
(Fig. 43). 
 
Fig. 43: MD refinement of TPA27 A-mode in the allosteric pocket. A: RMSD plot during 100 
ns of MD refinement of the ligand in monomer A (cyan) and monomer B (magenta), referred to 
the docking. B: superimposition of the monomers after 100 ns of MD refining: allosteric pocket 
is represented as internal surface (grey), ligand in monomer A is cyan and in monomer B is 
pink. The brown helix represents the other monomer. 
 
The A-binding mode of TPA27 was similar to the pose described for Ibu-
AM5 and Flu-AM1, in particular regarding the portion of the molecule shared 
with profen derivatives. Thus, the ligand is stabilised by hydrogen bonds 
between the carbonyl amide and the backbone of Gln273 (as seen for A-mode 
of Ibu-AM5 and Flu-AM1), and hydrophobic interactions of the methyl-
pyridine ring with Phe388, Leu380, Ile238 and Val270, and of the methyl on 
the chiral centre with Leu278. The different shape of the 4-((2-
(trifluoromethyl)pyridin-4-yl)amino)phenyl moiety, with respect to the 
biphenyl of Flu-AM1, allow more hydrophobic contacts with residues of the 
second monomer (Met454, His449 and Trp445), but also water-mediated 
hydrogen bond of the trifluoromethyl-pyridine moiety with sidechains of 
Ser254 and Glu453 at the interface with the other monomer (Fig. 44). 
Therefore, the presence of hydrogen bond donors and acceptors that 
characterize the TPA series with respect to the profen derivatives, contributed 
to stabilise the A-mode in the allosteric pocket.   
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Fig. 44: A-mode of TPA27 in monomer A refined after 100 ns of MD. Interacting residues are 
showed in sticks (brown, monomer B; green, monomer A). A) Hydrogen bond of TPA27 (cyan, 
in sticks) in B-mode. B) Apolar interaction in the binding pocket of the FAAH. The ligand 
TPA27 is represented in cyan by van der Waals spheres. 
 
The B-binding mode of TPA27 showed very distinct poses in the two 
monomers. As seen in the RMSD plot, the ligand in monomer A showed large 
fluctuations and filled an area near to the catalytic triad. On the contrary, the 
simulation in monomer B led to a stable binding in the CP (Fig. 45).  
 
Fig. 45: MD refinement of TPA27 B-mode in the allosteric pocket. A: RMSD plot during 100 
ns of MD refinement of the ligand in monomer A (magenta) and monomer B (yellow), referred 
to the docking. B: superimposition of the monomers after 100 ns of MD refining: allosteric 
pocket is represented as internal surface (grey), ligand in monomer A is pink and in monomer B 
is yellow. The brown helix represents the other monomer. 
 
The B-mode in the monomer B formed a water-mediated hydrogen bond with 
the sidechain of Ala275 and showed stacking interaction with Tyr271 and 
hydrophobic contacts with Met191, Leu192, Val270, Leu278 (Fig. 46). 
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Fig. 46: B-mode of TPA27 in monomer A refined after 100 ns of MD. Interacting residues are 
showed in sticks (brown, monomer B; green, monomer A). A) Hydrogen bond of TPA27 (cyan, 
in sticks) in B-mode. B) Apolar interaction in the binding pocket of the FAAH.  
 
Computational data about the binding mode of Ibu-AM5, Flu-AM1 and 
TPA27 do not allow a clear definition of the binding mode. QM/MM 
calculations are currently running in order to have a clearer picture of the 
binding energetics in order to establish the preferred binding mode of each 
ligand in the allosteric site.  
Nevertheless, we designed a series of derivatives of Ibu-AM5 and Flu-AM1, 
in order to get more information on the SAR that could lead to the selection of 
the best binding mode for each ligand. 
 
 6.4 Profen amide derivatives 
6.4.1 Ibu-AM5 derivatives 
Taking into account the binding hypothesis of (S)-Ibu-AM5 for the 
competitive and allosteric site, we designed a number of Ibu-AM5 derivatives 
by varying the chemical nature of the amide group in order to improve the 
SAR.   
Kinetic experiments highlighted how small substitutions should dramatically 
affect the inhibition mechanism and binding preferences of TPA and Ibu-am 
derivatives. Moreover, due to the mixed nature of Ibu-AM5 inhibition, we 
hypothesize that these compounds bind two different binding sites. In light of 
such considerations, limited information can be derived by SAR analysis, 
since we actually do not know if changes in the activity are due to changes in 
affinity toward the competitive site, the allosteric site or both. 
We firstly investigated the role of the pyridine nitrogen substitution (Table 
12). 
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Table 12: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compound Ibu-AM5, Ibu-AM48-49. 
 
The loss of the pyridine nitrogen worsened the affinity, in agreement with the 
(S)-Ibu-AM5 binding mode described in chapter 2. The nitrogen is indeed 
involved in a hydrogen bond with Trp531. The substitution of the methyl 
group of the pyridine moiety of TPA5 with the more polar hydroxyl group 
resulted in a reduction of activity (Ibu-AM50, Table 13). This result is in 
agreement with the binding mode proposed for the competitive site, wherein 
the methyl group fills a hydrophobic pocket formed by Leu404 and Ile407 
(mutated in mouse). In the putative allosteric binding mode, the methyl group 
fills a hydrophobic environment in the B-mode of Ibu-AM5, while the 
pyridine nitrogen is involved in hydrogen bond with Val270. 
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Table 13: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compound Ibu-AM50-53. 
 
To further explore the chemical features of the pockets filled by the methyl-
pyridine moiety of Ibu-AM5, we also designed a series of compounds bearing 
hydrogen donor and acceptor groups on a phenyl ring in the amide moiety 
(Table 13). The results demonstrated that the hydroxyl group on the phenyl 
ring induce loss of activity when introduced in position 2, but it is better 
tolerated in position 4 (Ibu-AM51). Hence, we designed compound Ibu-
AM52, which is the only compound of this series to show low micromolar 
activity for rFAAH, showing 7-fold increase in activity compared to Ibu-
am48. Therefore, Ibu-AM52 confirmed the need of a hydrophobic group in 
ortho to the amide bond, while demonstrated the possibility to exploit the 
para position for extra polar interactions. Among the putative binding mode 
found in the allosteric pocket, this behaviour would be in better agreement 
with both B-mode hypotheses of binding (Fig.  36 and 37), since the amidic 
portion points to the cytosolic environment where the 4-hydroxyl group might 
establish water bridged interactions with residues in the CP. On the contrary, 
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in the competitive site the methyl-pyridine moiety (Fig. 13) is tailored in a 
hydrophobic pocket, and therefore should not accommodate any substituent in 
position 4 of the phenyl ring. Therefore, we cannot exclude that Ibu-AM52 
could reveal a different mode of inhibition with respect to Ibu-AM5.   
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Table 14: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compound Ibu-AM5, Ibu-AM54-58. 
 
To explore the chemical requirements of the position 3 of the pyridine amide 
moiety we have designed compounds with halogen. The 3-chlorine derivative 
showed small reduction in activity as compared to Ibu-AM5, while the 
replacement of chlorine with bromine, iodine and trifluoromethyl groups 
improved the inhibitory activity. Among these, the 3-bromopyridine analogue 
Ibu-AM56 is the most potent FAAH inhibitor of the Ibu-am series with an 
IC50 value of 0.083 μM. It is noteworthy that the effects of the 3-chlorine and 
3-bromine substitution induce different effects in the Ibu-am and TPA series. 
The comparison of the activities of Ibu-AM54 with TPA27 and of Ibu-AM56 
with TPA24 revealed different structure-activity relationships, suggesting 
different binding modes for the two series, which is in agreement with our 
computational data. 
We also evaluated the effects of a polar group in place of the methyl group of 
Ibu-AM5. The comparison of Ibu-AM58 with Ibu-AM5 reveals that the 
replacement of the methyl with a hydroxyl group leads to a 4-fold reduction in 
activity, confirming the trend showed by the aryl analogues Ibu-am48 and 
Ibu-AM50. Therefore, the introduction of the hydroxyl group in position 3 of 
the pyridine ring is not favourable for the activity, as expected by the 
predicted binding modes, where 3-methyl group of Ibu-AM5 fills 
hydrophobic cavities in both competitive (Fig. 13) and allosteric (Fig. 36) 
binding sites. However, the comparison of Ibu-AM58 and Ibu-AM50 
activities indicates that the pyridine nitrogen increased the inhibitory activity 
by a factor of 4. (Table 14). 
6.4.2 Flu-AM1 derivatives 
On the basis of (R)-Flu-AM1 putative binding modes found for competitive 
and allosteric sites, we designed a number of Flu-AM1 derivatives. The first 
compounds synthetized and tested are reported in Table 15. 
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Table 15: Maximum percentage and IC50 values for inhibition of rat brain AEA hydrolysis by 
compound Flu-AM1-4. 
 
As a general observation, we found that the behaviour of Flu-AM1 derivatives 
correlate with the trends observed for Ibu-AM5 derivatives reported in 
paragraph 5.4.1. Indeed the 3-bromo-pyridine derivative Flu-AM3 is the most 
active of the series, while 3-CF3-pyridine (Flu-AM2) and the 2-methyl-4-
hydroxy-phenyl (Flu-AM4) show little improvements of activity with respect 
to the lead Flu-AM1.  This consideration is in good agreement with the 
reported binding modes in the competitive site. On the contrary, the Flu-AM1 
B-binding mode described for the allosteric site don’t show specific 
interactions of the methyl-pyridine moiety, that is not involved in any specific 
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interactions, being surrounded by water molecules, and it would be in better 
agreement with the A-binding mode. Therefore, more detailed investigations 
will be required in order to study the binding mode of these promising 
ligands. 
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7. Identification and rational design of novel peptides that 
interfere with the interaction between hUbA1/UbcH10. 
 
7.1 Introduction 
UbcH10 is a member of the ubiquitin conjugation enzymes (Ubc), a 
component of the anaphase-promoting complex and a key regulator of cell 
cycle progression [89], as it induces the ubiquitination and degradation of 
cyclins A and B [90]. Previous studies have indicated that UbcH10 
overexpression might be associated in the late stages of thyroid neoplastic 
transformation [91], and that high levels of UbcH10 correlate with most 
aggressive grade tumour in breast cancer [92]. Similar evidences have been 
found for several tumour types, such as ovarian [93], colorectal and brain 
cancers [94] and different lymphoma [95]. Moreover, in numerous cancer 
tissues the UbcH10 expression is relatively higher if compared with the 
adjacent non-malignant tissues. All these evidences point out that the aberrant 
expression of UbcH10 could promote tumour expansion through dysfunction 
of mitotic progression, leading to deregulation of cell growth as confirmed in 
both thyroid [94] and breast carcinoma [96], where the interference with 
UbcH10 appears to be potential target for developing an anticancer therapy 
based on the suppression of its specific biological function. 
A key step in the discovery of inhibitors of the UbcH10-mediated 
ubiquitination is the comprehension of the structural and mechanistic features 
that mediate conjugation of proteins to ubiquitin (Ub), a complex process that 
involves a three-step cascade mechanism characterised by growing specificity 
[96, see 97 for a recent review] (Fig. 47). Thus, the ubiquitin-activating 
enzyme (UbA1, also known as E1) initiates the ubiquitination cascade by 
catalysing the ATP-dependent adenylation of the Ub C-terminus (step I). The 
high-energy anhydride bond thus formed is attacked by the E1 active site 
cysteine (Cys632 in human UbA1), forming a thioester bond between E1 and 
Ub (step II). Then Ub is transferred to the active site cysteine of an Ub-
Conjugation enzyme (denoted E2), a process promoted by non-covalent 
binding of a second Ub molecule in the adenylation site (step III and IV). 
Finally, Ub is conjugated to its substrate with the aid of a protein ligase 
(known as E3), resulting in the covalent linkage of the Ub C-terminus to the 
ε-amino group of a lysine in the substrate (steps V and VI). In humans there 
are two E1 enzymes (UbA1 and UbA6) [98], over 30 distinct forms of E2 and 
about 500-1000 forms of E3, which is largely responsible for conferring 
specificity to ubiquitination [99]. 
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Fig. 47: Ubiquitin conjugation cascade. UbA1 consists of four domains: the Adenylation 
domain (AD), the First Catalytic Cysteine Half-domain (FCCH), the Second Catalytic Cysteine 
Half-domain (SCCH) and the Ubiquitin Folding Domain (UFD). I) UbA1 catalyzes the 
adenylation of the Ub C-terminus in an ATP-dependent process in the AD domain; II) the 
activated Ub forms a thioester bond with a conserved catalytic cysteine in the SCCH domain of 
UbA1 [Ub(T)]; III) UbA1 is loaded with a second Ub molecule in the AD domain, followed by 
its C-terminal adenylation [Ub(A)]; IV) the ternary UbA1,Ub(T)-Ub(A) thioester complex 
recruits E2 (e.g. UbcH10); V) the thioester-linked Ub is transferred to a conserved E2 cysteine 
(transthioesterification); VI) E3 mediates the binding of Ub to the target lysine e-amino groups. 
 
To the best of our knowledge, there is not a complete 3D model of the 
quaternary complex required for the transfer of Ub to the E2 Ubiquitin 
conjugation enzyme. In these studies we describe a computational strategy to 
build up the first structural model of the transient tetrameric complex between 
the doubly Ub-loaded human UbA1 (hereafter denoted UbA1~Ub(T)-Ub(A)) 
and UbcH10, as a member of E2 family.  
The work discussed in this chapter has been published in a peer-reviewed 
journal article [100] and it is the result of an interdisciplinary collaboration. S. 
Correale, A. Federico, P. Pallante, A. Fusco and E. Pedone performed protein 
expression and affinity assays; I. de Paola, L. Zaccaro and A. Galeone 
synthesised the peptides; C. M. Morgillo, F. J. Luque and B. Catalanotti 
performed computational calculations. 
 
7.2 Building of the 3D trimeric complex of hUbA1 with doubly loaded 
Ub 
The structural model of hUbA1 was built up by using 1Z7L and 3CMM 
structures as templates for the hUbA1 SCCH region (1Z7L) and for the AD, 
FCCH and UFD domains (3CMM), respectively. Moreover, the two 
conformations of S. cerevisiae UbA1 (scUbA1) found in the X-ray structure 
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3CMM were considered, leading to 3D models named UbA1_A and UbA1_C 
(see experimental section). The quality of the models was checked by 
considering a number of structural features, including stereochemical 
properties, the compatibility between the amino acid sequence and the 
environment of amino acid side chains, and the patterns of non-bonded 
interactions. Taking into account the similar scores obtained for the two 
models and their structural resemblance (RMSD = 1.2 Å), MD refinement 
was accomplished only for UbA1_C. A stable structure was obtained after the 
first 5 ns of the trajectory (Fig. 48A). Nevertheless, the structure of each 
domain was very stable along the trajectory, as demonstrated by the stability 
of the RMSD of the single domains (Fig. 48B). 
 
Fig. 48: A: Time evolution (ns) of the RMSD (Å) of the UbA1_C model: hUbA1 apo (red), 
hUbA1∼Ub(T) (yellow), hUbA1∼Ub(T)-Ub(A) (green) and hUbA1∼Ub(T)-Ub(A)-UbcH10 
(black). B, C and D: Structural preservation of the structure of each region. of: hUbA1 apo (B), 
hUbA1-Ub(T) (C) and UbA1∼Ub(T)-Ub(A) (D), AD (black), UFD (green), SCCH (red) and 
FCCH (blue). 
 
To build up the tetrameric complex between hUbA1, Ub(T), Ub(A) and 
UbcH10, we first modelled the hUbA1~Ub(T) thioester complex, which was 
subsequently used to dock a second Ub molecule in the AD domain. 
Modelling the binding mode of Ub(T) is challenged by the lack of structural 
and biochemical information about this interaction, and by the covalent 
linkage of Ub, which is an unusual feature in protein-protein docking. To this 
end, was adopted a multistep strategy that included the use of two protein-
protein docking webservers, HADDOCK [101] and RosettaDock [102], in 
order to disclose the non-covalent interfaces between the E1 and Ub(T). 
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Accordingly, we first docked Ub to hUbA1 using HADDOCK by restraining 
the contact between Cys632 (UbA1) and Gly76 (Ub). Among the 9 clusters 
that embody the 200 best structures yielded by HADDOCK (Table 16), 
solutions were chosen on the basis of four criteria: i) the distance from the 
sulphur atom of Cys632 and the carboxylic oxygen of Gly76, ii) the total 
score, iii) the total number of poses, and iv) the buried surface area. The 
selected poses lead to a distance lower than 3.8 Å, and are characterized by a 
high score, a large number of poses, and a large burial of surface area (see 
Table 16).  
 
Table 16: HADDOCK results for the dimeric complex hUbA1-Ub(T). The structural data 
include the distance (Å) from the sulphur of the hUbA1 Cys632 to the C-terminal Gly76 of 
Ub(T). The energy data report the score of the docked structures obtained from HADDOCK 
and from SIE (kcal/mol). Lowest energy result for clusters 3 and 2 (named respectively Ha and 
Hb) were selected for Rosetta calculations. 
 
These poses (denoted Ha and Hb) mainly differ in the orientation of Ub 
relative to the SCCH domain (Fig. 49A). In the lowest energy solution (Ha), 
Ub forms contacts with SCCH, mainly through ionic and polar interactions, 
and FCCH, primarily through hydrophobic interactions via the Ile44 patch, 
which is known to be involved in other non-covalent interactions of Ub, such 
as in the recognition of UbcH5c, UEV and GLUE domains [103]. In the 
second pose (Hb), Ub only showed polar contacts between residues in the Ub 
tail with the SCCH domain. 
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Fig. 49: Model of hUbA1-Ub(T) complex. A) Comparison of the best two binding modes of Ub 
resulting from HADDOCK calculation, Ha and Hb, shown in yellow and orange, respectively. 
Terminal Ub-Gly76 and catalytic UbA1-Cys632 are highlighted in spheres coloured by atom 
type. B) Detail of hUbA1∼Ub(T) interactions in the lowest energy MD frame (time 9.6 ns). 
Apolar hydrogens were omitted for sake of clarity. Colour code: hUbA1, grey; Ub(T), yellow; 
van der Waals interactions are highlighted with transparent Connolly surfaces. Carbons are in 
cyan, nitrogen in blue, oxygens in red, sulphur in yellow and hydrogens in white. 
 
The two poses were then checked using RosettaDock. The best ranked 
solution turned out to be very similar to the best HADDOCK solution (Ha), as 
noted in a RMSD of 0.82 Å. In contrast, calculations started from pose Hb 
yielded solutions that showed significant structural differences with regard to 
the initial structure. Therefore, due to the structural consistency of pose Ha, it 
was chosen as a model of the hUbA1~Ub(T) complex and subsequently 
refined by MD simulations, which led to a stable trajectory after the first 2 ns 
(see Fig. 48A, C). The refined structure supports the hydrophobic contacts 
between residues Leu8, Ile44, Val70 and Leu73, which interact with FCCH 
residues Y286, Met223, Val277, Leu178 and Thr233. The hydrophobic 
interactions involving the Ile44 patch were also reinforced by ionic 
interactions between Arg42 (Ub(T)) and Asp236 and between Arg74 (Ub(T)) 
and Asp811 (Fig. 49B). 
The trimeric complex was obtained through docking of Ub to the AD site and 
subsequent MD refinement, which led to a stable trajectory after the first 2 ns 
(see Fig. 48A, D). The 3D structures closely resembled the X-ray template 
3CMM (RMSD of 1.1 Å; Fig. 50A). Three different interfaces might be 
identified: i) the loop pocket defined by hUbA1 residues Tyr618, Ser621, 
Glu626, Arg515, Asn512, Asn516 and Arg551 interacting with Ub(A) tail 
residues Arg72, Arg42 and Arg74 and AMP (Fig. 50B); ii) an hydrophobic 
patch formed by the Ub residues Leu8, Ile44 and Val70 that form contacts 
with a hydrophobic area in the hUbA1 AD region formed by residues Phe933 
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and Phe926 (Fig. 3-C); and iii) the polar interface formed by Ub(T) residues 
Thr9, Lys11, Thr12, Asp3 interacting with the FCCH region, mainly with 
residues Glu243, Arg239 and Asn212 (Fig. 50C). Moreover, interactions 
between Ub(T)-Lys48 and Asp920 and Glu938, not present in the 3CMM 
structure, were also found. 
 
Fig. 50. Model of hUbA1-Ub(T)-Ub(A) complex. A) Superimposition of the hUbA1∼Ub(T)-
Ub(A) model C_Ha on the crystal structure 3CMM_C; B) Detail of the main interactions of 
Ub(A) and AMP in the hUbA1 loop pocket; C) Detail of the main interactions between Ub(A) 
and hUbA1: hydrophobic and polar interface. AMP is highlighted in CPK. Apolar hydrogens 
were omitted for the sake of clarity. Colour code: hUbA1, grey; Ub(T) yellow; Ub(A), orange; 
scUbA1, blue; scUb(A), green. 
 
Finally, during our studies, a novel structure of the scUbA1 loaded with two 
ubiquitin molecules was released in the PBD with the name 4NNJ [104]. The 
superimposition of the model of hUbA1-Ub(T)-Ub(A) complex obtained with 
our incremental strategy to the crystal structure (chains C, D, E) leads to a 
RMSD of 1.5 Å (determined for the Ca carbon atoms), and showed a position 
of Ub(T) very similar to the pose C_Ha selected in our calculations (Fig. 51), 
thus supporting the reliability of our model. 
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Fig. 51: Superposition of the backbone for the X-ray structure 4NNJ and the 3D model of the 
ternary complex. Front and side views are shown in the left and right pictures, respectively. 
Colour code: hUbA1, grey; Ub(T) yellow; Ub(A), orange; scUbA1, magenta scUb(A), green, 
scUb(A), Cyan. 
 
7.3 Building of the quaternary complex hUbA1~Ub(T)-Ub(A)-
UbcH10 
The hUbA1~Ub(T)-Ub(A) model was the starting point for the docking with 
UbcH10. In order to make a more exhaustive sampling, up to four different 
starting points were considered for docking calculations (see experimental 
section). HADDOCK calculations yielded 80 clusters. The results were 
filtered by selecting only poses where the distance from the sulphur atom of 
the UbcH10 catalytic cysteine (Cys114) to the carbonyl carbon of the C-
terminal Gly in Ub(T) was lower than 20 Å, considering this limit as 
indicative of the side of UbcH10 facing the SCCH region. Moreover, this 
criterion is consistent with the distance between the Cys residues involved in 
the transthiolation reaction in the crystal structure 2NVU, representing the 
tetrameric complex of the NEDD8 system. Only six clusters satisfied the 
distance cutoff. Among these clusters, Ub(T) adopted the Ha binding mode in 
five cases, and the Hb arrangement was found in a single case. This suggests 
that the Ha binding mode position was better suited to accommodate the E2 
partner within the E1 groove with the catalytic cysteines facing each other. 
Table 17 shows the distinct poses ranked according to HADDOCK score as 
well as to the binding free energy of the complex calculated with the SIE 
method using the snapshots collected in the MD simulation. A_Ha_L2 
emerges as the best pose according to HADDOCK score and SIE binding 
affinity. Both HADDOCK and SIE scores are consistent in suggesting 
C_Ha_R and C_Ha_L as feasible poses. The structures of these complexes 
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differ by around 5.5 Å relative to A_Ha_L2. The A_Ha_L1 and A_Ha_R 
poses were structurally similar to A_Ha_L2 (RMSD of 3.3 Å) and Ca_Ha_R 
(RMSD of 4.3 Å), respectively. However, SIE calculations predict that they 
are less stabilized compared to A_Ha_L1 and A_Ha_R. Finally, C_Hb_R was 
discarded due to the low energetic score. 
 
Table 17. Comparison of structural and energy data for selected docking results of the 
quaternary complex. 
 
It is experimentally known that the N-terminal helix and β1β2 loop of E2 are 
directly involved in the formation of the complex [105-109]. In particular, 
mutational and structural studies disclosed the main role of two basic 
residues, conserved in the E2 family (positions 33 and 37 in UbcH10 
numbering), in assisting the binding to E1. We have therefore examined the 
role played in the selected models by i) the conserved acidic residues of the 
UFD region of hUbA1 (i.e. Glu1037, Asp1047 and Glu1049) and ii) the 
conserved basic residues of the N-terminal helix of UbcH10 (i.e. Lys33′ and 
Gln37′). It is worth noting that while a basic residue in position 33 is 
conserved in all the members of the E2 family, position 37 shows a higher 
variation, albeit basic or polar residues are generally found in this position. To 
this end, the best three solutions (A_Ha_L2, C_Ha_R and C_Ha_L) were 
subjected to a virtual alanine scanning analysis in order to evaluate the 
contribution of these residues to the E1–E2 interaction. Even though the 
results (Table 18) did not show significant interactions (defined as ΔΔG ≥ 
−0.5 kcal/mol) with Gln37′, the best three models showed a significant 
contribution to the binding of at least one residue from the N-terminal helix 
and one residue from the UFD region of UbA1. For the sake of comparison, 
no significant contribution was found for the mutations in the N-terminal 
helix for poses A_Ha_L1 and A_Ha_R. In fact, only a single mutation in 
hUbA1 (Asp1047→Ala) was found to lead to a significant destabilization. 
This finding, together with the structural resemblance to A_Ha_L2 and 
Ca_Ha_R and the lower SIE binding free energy (see above), led to their 
exclusion from further refinements. 
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Table 18: Alanine scanning. 
 
The three models were further refined by running a series of 50 ns MD 
simulations, and the binding free energy was determined from SIE 
calculations performed for the snapshots sampled in the last four 10 ns 
windows. The results consistently showed that the best binding affinity was 
obtained for model C_Ha_R (−26.6±0.2 kcal/mol), it being more favorable by 
6 and 9 kcal/mol compared to A_Ha_L (−20.2±1.4 kcal/mol) and C_Ha_L 
(−17.2±1.5 kcal/mol) models. On the basis of the preceding findings, the 
C_Ha_R model was further refined by extending the MD simulation to 500 
ns. The analysis of the trajectory revealed a progressive stabilization of the 
complex, leading to a binding affinity close to −31 kcal/mol in the last 250 ns 
(Fig. 52A). The alanine scanning analysis also demonstrated that the residues 
known to be critical to E1–E2 complex formation contributed significantly to 
the protein-protein interaction with the only exception of Gln37′ (Fig. 52B).  
 
Fig. 52. Energetic analysis. A) SIE values (kcal/mol) determined for the E1-E2 interaction 
along the trajectory (averaged for 20 ns windows). B) Contribution of key residues as derived 
from alanine scanning in UbcH10 N-terminal helix and the hUbA1 UFD region during the MD 
simulation of the model C_Ha_R. Colours: Glu1037, orange; Asp1047, violet; Glu1049, light 
green; Lys33′, bordeaux: Gln36′, blue; Gln37′, dark green. 
 
During the MD run we observed a change in hUbA1 associated to the rotation 
in opposite directions of the UFD and SCCH domains with respect to the AD 
domain (by 20° and of 13°, respectively, as calculated with DynDom [110]). 
This conformational change caused the widening of the groove defined by the 
three domains, thus allowing a closer contact between hUbA1 and UbcH10, 
leading to an increase of the interaction surface (Table 19) and the gradual 
decrease of the distance between the UbcH10 catalytic cysteine and the Ub(T) 
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C-terminal glycine crosslinked to UbA1-Cys632 until it stabilised at around 8 
Å (Fig. 53).  
 
Table 19: Time evolution of interaction surface (Å2) for selected domains in hUbA1. 
 
 
Fig. 53: Analysis of the distance between the sulphur atom of the UbcH10 Cys114 and the 
carbonyl group of the crosslinked Ub(T) terminal glycine during the 500 ns unconstrained MD. 
 
Analysis of the last 50 ns of the trajectory revealed the presence of two main 
interaction surfaces, which involve contacts between i) UbcH10 helix H1 and 
β1β2 loop and hUbA1 UFD domain, and ii) the hUbA1 Cys-cap loop and 
Ub(T) (Fig. 54). 
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Fig. 54. Model of the hUbA1-Ub(T)-Ub(A)-UbcH10 complex. A) Average structure of last 20 
ns of MD simulation of the C_Ha_R model. The catalytic cysteines, the thioester bond and 
AMP were highlighted in spheres. Detail of interactions between B) UbcH10 and SCCH 
region, C) UbcH10 and Ub(T) and D) UbcH10 and UFD region. Catalytic cysteins and the 
thioester bond were highlighted in CPK. Apolar hydrogens were omitted for the sake of clarity. 
Colour code: hUbA1, grey; scUbA1, blue; Ub(T) yellow; Ub(A), orange; UbcH10, violet. The 
van der Waals interactions are highlighted with transparent Connolly surfaces. 
 
7.4 Final refinement of the tetrameric complex 
Although MD simulations led to a progressive refinement of the quaternary 
complex, the distance between residues Cys114 in UbcH10 and the terminal 
glycine of the crosslinked Ub(T) was still too large (~8 Å; Fig. 53) as to 
mimic a state that resembles the catalytic arrangement of the interacting 
proteins. Inspection of the final MD structure showed that a closer approach 
between hUbA1 and UbcH10 was prevented by the Cys-cap loop, which 
retained the orientation found in the PDB template 3CMM. In contrast, in the 
available structure of the E1–E2 complex (PDB structure 4II2) the Cys-cap 
loop is not assigned, thus suggesting a large flexibility in the covalent 
construct that mimics the thioester crosslinking event. We have therefore 
forced the approach of UbcH10 by using steering forces applied on the 
sulphur of the UbcH10 Cys114 toward the carbonyl group of the crosslinked 
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Ub(T) C-terminal glycine, after manual removing of the Cys-cap loop. 
Steered molecular dynamics (SMD) simulations allowed us to reduce the 
distance between those atoms from 8 Å to 3.2 Å in 8 ns. After loop 
reconstruction, the final structure was refined in a 50 ns MD simulation, 
leading to a stable trajectory (Fig. 55).  
 
Fig. 55: Analysis of the distance between the sulphur of the UbcH10 Cys114 and the carbonyl 
group of the crosslinked Ub(T) C-terminal glycine during the 50 ns unconstrained MD of the 
final model obtained after SMD. 
 
This approach led to a closer fitting of UbcH10 into the groove defined by the 
UFD and SCCH domains, increasing the total interaction surface, especially 
between hUbcA1 SCCH and the UbcH10 region around the catalytic cysteine, 
in better agreement with the crystal structure of the E1–E2 crosslinked 
construct (Table 19). Moreover, SIE calculations revealed an increase of the 
binding energy to −42.7 kcal/mol. 
Comparison of the refined model with the recently reported X-ray 
crystallographic structure of the trimeric complex of S. pombe Uba1-Ub-
Ubc4 (PDB ID: 4II2) lends support to the theoretical 3D model of the 
quaternary complex. Thus, after deletion of the E2 partners (UbcH10 and 
Ubc4) and the additional Ub present in the quaternary complex, superposition 
of the backbone Cα carbon atoms leads to a positional RMSD of 2.5 Å, which 
indicates the similar structural arrangement of the AD, SCCH and UFD 
domains in the two complexes (Fig. 56). Furthermore, retention of the E2 
partners in the superposed structures leads to an RMSD value of 2.6 Å, thus 
suggesting a similar arrangement in the trimeric and quaternary complexes. 
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Fig. 56: Superposition of the UbA1 and Ub(A) backbone for the X-ray structure 4II2 (grey) and 
the 3D model of the quaternary complex (Green). Front and rear views are shown in the left 
and right pictures, respectively. 
 
The analysis of the snapshots sampled in the last 20 ns of the trajectory 
allowed us to identify key interactions in the complex, which involve three 
interfaces: i) the contacts between the hUbA1 UFD domain and the UbcH10 
helix H1 and β1β2 loop, ii) the interaction between the hUbA1 SCCH domain 
and Ub(T) with the region surrounding the UbcH10 Cys114', involving 
residues from the 3–10 helix and helices H2 and H3, and iii) the contacts 
between the hUbA1 crossing loop and Ub(A) with UbcH10. 
The first interface (Fig. 57) comprises the UbcH10 residues Lys33′ and 
Gln37′, which are experimentally known to be critical for the interaction 
between E1 and E2 [107-109]: Lys33′ interacts with Asp1042 and with 
Ser1044, and Gln37′ is hydrogen-bonded to the backbone oxygen of Cys1040 
and the hydroxyl group of Thr988 (Fig. 57F). Moreover, hydrogen bonds 
were also formed between the side chains of Gln36' and Asp1042, between 
Tyr91 and Asp1047, and between the N-terminal Pro30′ with Glu1049 (Fig. 
57F). Finally, the ionic interactions were supplemented by hydrophobic 
contacts involving hUbA1 residues Met989, Val994, Met996, Phe1000, 
Phe1001, and UbcH10 residues Leu42′, Pro54′, Leu59′ and Phe60′ (Fig. 57E). 
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Fig. 57. Final refined model of the tetrameric complex. A) Average structure of the last 20 ns of 
MD simulation of the model after SMD. B) Detail of the UbcH10-Cys-cap loop interactions. C) 
Detail of UbcH10-Cys region involved in hydrophobic interactions; D) Detail of the UbcH10-
Cys region involved in polar interactions; E) Detail of the hydrophobic interactions between 
hUbA1 UFD and UbcH10. F) Detail of the polar interactions between hUbA1 UFD and 
UbcH10. Colour code: hUbA1, grey; Ub(T) yellow; Ub(A), orange; UbcH10, violet. Catalytic 
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cysteins were highlighted in spheres. Apolar hydrogens were omitted for the sake of clarity. 
Van der Waals interactions are highlighted with transparent Connolly surfaces. 
 
Interactions between the hUbA1 SCCH domain and the region surrounding 
the E2 catalytic cysteine were mainly characterized by a number of ionic and 
polar interactions between residues from H3 and H4 helices of UbcH10 
(Glu154', Lys164', Lys172' and Tyr165') and residues from the hUbA1 Cys-
cap loop (Gln728, Lys806, Glu813, Asp811 and Asp822) (Fig. 57B), while 
the region around the UbcH10 catalytic cysteine, including residues in the 3–
10 helix, were involved in interactions with the residues around hUbA1 
Cys632 and Ub(T). In particular, two main clusters of interactions are formed: 
i) the first, mainly based on hydrophobic interactions, between the UbcH10 
helix H3 (Pro147′, Ala153′ and T150′) with the UbA1 coiled stretch between 
H24 and H25 (Phe637, Phe729 and Phe741), also supported by hydrogen 
bonds between Asn728 with His151′ and Thr150′ (Fig. 57C); ii) the second 
mainly involves residues closer to the catalytic cysteines, such as the ionic 
contact between the UbcH10 Asp145′ with UbA1-Lys746 and Ub(T)-Arg 72, 
and interactions between charged residues in the UbcH10 3–10 helix 
(Asp116′, Asp120′ and Lys121′) with Ub(T) residues (Gln40, Arg74, Asp39) 
and with the hUbA1 FCCH domain (Glu237) (Fig. 57D). 
These findings demonstrated that the crosslinked Ub plays a key role in the 
transthiolation intermediate with UbcH10. In particular, MD simulations 
highlighted that the approach of the catalytic cysteines induced a rotation of 
25° of Ub(T) with respect to hUbA1 and a rearrangement of the Ub(T) pattern 
of interactions showed in models lacking E2 (Fig. 58).  
 
Fig. 58. Rotation of the Ub(T) induced by UbcH10 interaction in the final quaternary model 
with respect to the UbA1~Ub(T) model. Superimposition was made on the Cα atoms of the 
SCCH and FCCH domains. Colour code: Final quaternary complex model: hUbA1, grey; 
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UbA1~Ub(T) model: UbA1, black; Ub(T), magenta; Arg74 in the two models is shown as 
licorice. Apolar hydrogens were omitted for sake of clarity. 
 
In particular, in absence of E2 Arg74 was hydrogen-bonded to Cys-cap 
residues (Asp811 and Gln812), while in the final model it was involved in 
ionic interactions with UbcH10-Glu120′ and Asp116′, and with Glu237, 
bearing to the hUbA1 FCCH domain. These data support the hypothesis that 
products of the transthiolation reaction might be released upon a process 
involving the rearrangement of the Ub(T) binding to E1, driven by the 
charged residues in the region surrounding the catalytic cysteine of E2. 
Finally, we also observed some interactions in the loop region of hUbA1, in 
particular hydrogen bonds between the side chain of Asn622 with the 
backbone of UbcH10-Tyr 91′ (Fig. 57F), and between the backbone of Ser628 
and the side chain of Glu120' (Fig. 57D). A representative snapshot of the 3D 
model is available as supplemental PDB file. 
 
7.5 Rational design of peptides that interfere with the formation of 
the tetrameric complex 
On the basis of the 3D model of the quaternary complex, we have designed 
six peptides as molecular probes in order to calibrate their ability to interfere 
the binding of UbcH10. This strategy was motivated by two main reasons. 
First, the identification of short peptides that mediate protein-protein 
interaction seemed a priori effective for disrupting the protein-protein 
recognition and binding. While other strategies, i.e. introduction of specific 
mutations, may also be envisaged, it is unclear whether single-point mutants 
might lead to a significant destabilization of the complex or even to impede 
the formation of the quaternary complex. Second, since our ultimate goal is 
the design of compounds that might disrupt the ubiquitilation process, testing 
a series of suitably chosen short peptides represents a valuable proof of 
concept for supporting the potential therapeutic effect of peptidomimetics. 
Specifically, the peptides were designed to examine the capability of hUbA1 
stretches that contribute to the protein-protein interface with UbcH10 (Fig. 
59).  
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Fig. 59: Strategy of peptide design, highlights of the hUbA1 regions used to design the 
peptides. Colour code: hUbA1, grey; Ub(T) yellow; Ub(A), orange; UbcH10, violet; S1 and S2 
red; U1 and U2 green; L1 and L2 blue. 
 
In particular, we have designed two peptides per interface, which will be 
denoted S for SCCH region, L for cross loop, and U for UFD (Table 20). In 
the UFD region peptides U1 and U2 were selected to test the relevance of the 
acidic residues in mediating the binding of the UbcH10 H1 helix. In the 
SCCH region peptide S1 was chosen to test the role of the Cys-cap in binding 
UbcH10, while peptide S2, corresponding to helix H19 in the SCCH region, 
was designed as negative control, since the 3D model revealed the lack of any 
interaction in the complex. Finally, peptides L1 and L2 were chosen to 
explore the role of the cross loop region in assisting the interaction with 
UbcH10. All the peptides were synthesized as biotinylated derivatives by 
solid phase method and purified by RP-HPLC. Unfortunately, S1 and U2 
were insoluble and so not testable in binding assays. The ability of the soluble 
peptides to bind recombinant GST-UbcH10 was checked by ELISA, utilizing 
GST as control (data not shown). 
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Table 20. Sequence and binding assays results of the designed peptides. 
 
The best results (Table 20) were obtained with U1 and L2, which were found 
to bind UbcH10 with an apparent KD of about 10 and 20 µM, respectively. In 
order to confirm that the binding of U1 and L2 peptides was sequence-
dependent, two scrambled peptides were synthesized, ScrU1 and ScrL2. The 
results demonstrated that these peptides exhibited a very poor binding, much 
weaker than U1 and L2, which might then be considered indicative of native 
protein-protein interactions. In particular the good affinity showed by U1 
allowed us to validate the role of the acidic residues of the UFD region in 
binding E2, thus giving confidence to our 3D model. The U1 peptide, indeed, 
contained D1047 and E1049, two of the three acidic residues involved in the 
hUbA1 UFD-UbcH10 H1 interface. Unfortunately, the low solubility of U2 
did not allow us to verify the role of E1037, which is the third residue proven 
to be involved in the interaction by mutagenesis studies. Similarly, the results 
obtained for L2 support the role of Gln622 in assisting the interaction of the 
crossover loop with UbcH10, in agreement with the 3D model. The low 
affinity showed by L1 peptide, which contains Gln622 at the N-terminus side 
of the sequence, might be indicative of the importance of flanking residues in 
L2 binding. Finally, the results obtained from the SCCH peptides allowed us 
to exclude a role in the binding of the helix region corresponding to S2, as 
expected for this peptide, which was designed as negative control. 
Overall, the results support the involvement of the selected peptides in 
mediating the protein-protein interactions in the hUbA1~Ub(T)-Ub(A)-
UbcH10, which in turn reinforces the reliability of the 3D model built up for 
the quaternary complex between E1, E2 and Ub partners. On the other hand, 
they also demonstrate the feasibility of interfering the formation of the 
complex, which paves the way to the structure-based design of 
peptidomimetics for UbcH10-related anticancer strategies. 
 
7.6 Conclusions 
By combining homology modelling, protein-protein docking, classical and 
advanced MD simulations, the structural features of the proposed model have 
allowed us to identify the regions that mediate the recognition between the 
interacting proteins. In turn, this information has been used to examine the 
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reliability of the structural model through experimental assays performed to 
evaluate the binding affinities of a number of short peptides that were suitably 
chosen from the contact region between interacting partners in the complex. 
Overall, this information can be valuable to gain insight into the specificity of 
recognition between E1 and E2 partners, as well as for the design of 
peptidomimetic compounds that can bind selectively to E2s and inhibit the 
ubiquitination process in pathological disorders.  
 
7.7 Experimental section 
7.7.1 Homology building 
The amino acid sequence of human UbA1 (hUbA1) was retrieved from the 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov; 
accession ID P22314). To find suitable templates for homology modelling, a 
BLASTP search was performed against the Protein Data Bank. At the 
beginning of this work, the search identified three templates: i) the crystal 
structure of mouse Ubiquitin-Activating Enzyme (PDB code 1Z7L; 2.8 Å 
resolution) [111], which covers 25% of the query sequence corresponding to 
the SCCH domain (sequence identity of 96%), ii) the crystal structure of the 
Saccharomyces cerevisiae UbA1 (scUbA1) - Ub complex (PDB code 3CMM; 
2.7 Å resolution) [112], which covers 98% of the query sequence (sequence 
identity of 53%; similarity 71%), and iii) the NMR solution structure of a 
fragment of mouse UbA1 (PDB code 2V31) [113], which covers 10% of the 
query sequence corresponding to the FCCH region, with sequence identity of 
93%. This latter structure showed that only the core region of FCCH was 
structured. Therefore, homology building was accomplished by using 1Z7L as 
template for the hUbA1 SCCH region (residues 629–884; hUbA1 numbering 
will be followed unless otherwise noted), and 3CMM as template for the AD, 
FCCH and UFD domains (residues 1–628 and 885–1057). Finally, since 
chains A and C in the X-ray structure 3CMM differ by a rigid-body rotation 
of the UFD domain, hUbA1 was modelled using the two monomers, leading 
then to two models hereafter designated UbA1_A and UbA1_C. 
The ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) [114] program 
was used for sequence alignment. The 3D structure of the target protein was 
modelled using SWISSMODEL [115]. The secondary structure of the target 
protein was assigned using DSSP [116]. Coordinates for two loops with 
undetermined coordinates in the UbA1 template structure (residues 812–824 
and 964–969) were built up using the loop building ProMod tool [117] by 
scanning through the loop database in SWISSMODEL. The models were 
refined on the basis of energy minimization by GROMOS96 [118] and the 
models were validated for the 3D–1D profile with VERIFY3D [119], non-
bonded interactions with ERRAT2 [120] and stereochemical qualities with 
PROCHECK [121] and WHATCHECK [122]. The comparison of the final 
model with the recently released structure of Schizosaccharomyces Pombe 
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UbA1 (spUbA1; PDB code 4II3) revealed similar homology parameters with 
hUbA1 (covered sequence 94%; sequence identity of 54%; similarity 70%) 
and a RMSD for the backbone atoms of 1.6 Å, thus confirming the reliability 
of the model. 
7.7.2 General strategy for docking calculations 
The 3D model of the quaternary complex between hUbA1, two Ub molecules 
and UbcH10 was determined by using an experimentally guided incremental 
strategy that relies on the building and refinement of models for the dimeric 
and trimeric complexes. Thus, we first explored the recognition between 
hUbA1 and Ub, leading to the UbA1~Ub(T) complex (Ub(T) stands for Ub 
bound to E1 through a thioester bond). Next, this model was used to build up 
the ternary UbA1~Ub(T)-Ub(A) system (Ub(A) denotes Ub bound to the AD 
domain). Finally, this model was the starting point for assembling the 
quaternary complex, UbA1~Ub(T)-Ub(A)/UbcH10. To this end, we adopted a 
computational approach that combines protein-protein docking, guided by the 
available structural information, and subsequent refinement through MD 
simulations (see below). 
In order to generate the structural models, two docking programs were used: 
HADDOCK [101] and RosettaDock [102]. HADDOCK uses experimentally 
derived data, in conjunction with the available structures, to carry out flexible 
data-driven docking of proteins. Residues that are known to be implicated in 
the protein-protein recognition are designated active and are used to introduce 
suitable restraints to drive the docking process (i.e, the so-called ambiguous 
interactions restraints; AIRs). HADDOCK expert interface was used to 
generate a reasonable rough complex, which was subsequently refined with 
the HADDOCK refinement interface. 
To assess the initial orientation of the interacting partners in order to check 
the suitability of the restraints to be imposed in HADDOCK calculations (i.e., 
the extension and solvent accessibility of the region comprising passive 
residues, which are solvent-exposed residues that surround the active ones) 
the mutual complementarity of the interacting partners was first explored by 
superposing the structures of Uba1 and Ub(T) in the X-ray structure of the 
APPBP1-Uba3~NEDD8-NEDD8-Ubc12 complex [105] (PDB entry 2NVU). 
A list of the restraints used in calculations is given in Table 21. 
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Table 21: List of the active residues used in each docking step. 
 
Finally, the RosettaDock server performs a local docking searching for 
conformations near the starting 3D structure in order to find the optimal fit 
between the partners. It was then used to calibrate the models derived from 
HADDOCK. 
7.7.3 The UbA1~Ub(T)-Ub(A)-UbcH10 complex 
Following the incremental docking strategy, the dimeric UbA1~Ub(T) system 
was generated using as input structures the previously generated hUbA1_A 
and hUbA1_C models, and the NMR structure of human Ub (PDB ID 2K6D) 
[123]. For HADDOCK calculations, the active residues were only those 
involved in covalent interactions, i.e. UbA1 Cys632 and Ub Gly76, and 
passive residues were defined as neighbouring residues in a range of 8.5 Å 
from the active ones. Residues in the Ub tail (residues 70–76) and in the loop 
above the catalytic cysteine, whose coordinates were undetermined in 
template structures (residues 803–819), were set as fully flexible during all 
stages of the docking protocol. Since RosettaDock accepts a maximum of 600 
residues, docking was performed using a truncated form of UbA1 that retains 
the residues pertaining to the interaction domain. Taking into account that 
RosettaDock allows the sliding of proteins around 8 Å, a binding region that 
includes residues 216–296 and 627–888 was defined. 
The ternary complex was generated taking into account experimental 
information taken from the PDB structure 3CMM, in which Ub is bound to 
the AD domain of scUbA1. In HADDOCK calculations the active residues 
were those known to participate in the binding between UbA1 (Arg239, 
Asp576, Tyr600) and Ub (Asp32, Arg72, Gly75, Gly76). Passive residues 
were automatically defined as neighbours in a range of 8.5 Å from active 
residues. Besides the Ub tail, full flexibility was also given to residues of the 
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UbA1 crossover loop (residues 592–630) to facilitate the accommodation of 
the Ub tail. 
Finally, to build up the 3D model of the quaternary complex, the UbcH10 
structure was taken from PDB ID 1I7K. Let us note that this structure is 
functionally active even though it lacks the first 30 residues at the N-terminus 
[124]. Note also that Ser114 in the crystal structure was mutated to Cys to 
restore the native sequence. In order to enhance the sampling in predicting the 
quaternary complex, four starting structures of the UbA1~Ub(T)-Ub(A) 
complex were generated by combining the two UbA1 models (UbA1_A and 
UbA1_C) with two orientations of Ub in the UbA1~Ub(T)complex (denoted 
Ha and Hb; see below). Hence, four ternary models were used to build up the 
3D structure of the quaternary complex. Active residues in HADDOCK 
calculations comprised those involved in E1–E2 interactions based on 
mutagenesis studies [105-109]: Glu1037, Asp1047 and Glu1049 in UbA1 
(numbering for the UbA1-Ub2 complex), and Lys33′ and Gln37′ in UbcH10. 
Moreover, the two catalytic cysteine residues (Cys632 in UbA1 and Cys114′ 
for UbcH10) involved in the transthiolation process were also treated as active 
residues in order to guide the complex formation. Passive residues were 
defined as neighbours in a range of 8.5 Å from active residues. Residues of 
the UbA1 crossover loop (residues 592–630) and the Ub tail (residues 70–76) 
were also flexible. Each ternary model was docked twice with UbcH10 
structure yielding a total of 80 clusters. 
7.7.4 Molecular Dynamics 
MD simulations were performed to refine the different complexes. To this 
end, each complex was immersed in a pre-equilibrated octahedral box of 
TIP3P water molecules, and the system was neutralized. The final systems 
contained between 93000 and 99000 atoms. All simulations were performed 
with the ff99SB force field [63]. The thioester bond between Ub(T) Gly76 
and UbA1 Cys362 was manually added, and suitable force field parameters 
were derived using CH3CH2SCOCH3 as a representative model. The AMP 
position was derived from the ATP molecule as found in the PDB structure 
2NVU. To this end, the AD domain of the UbA1~Ub(T)-Ub(A) model was 
superimposed to the AD domain of NAE1/UbA3. On the other hand, the 
phosphodiester bond between Ub(A) Gly76 and AMP was manually added, 
and the force field parameters for the phosphodiester linkage between UbA1 
Cys632 and Ub(T) Gly76 were derived using CH3OP(O)2OCOCH3 as a model 
system. 
For each complex the geometry was minimized, equilibrated and subjected to 
MD production run, following the general protocol described in §3.2. The 
structural analysis was performed using in-house software and standard codes 
of Amber 12. 
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7.7.5 Steered Molecular Dynamics and refinement of the final 
complex 
Comparison of the final MD structures and the recently solved X-ray structure 
of Uba1 in complex with Ubc4 (PDB entry 4II2; [125]) showed that the loop 
masking the hUbA1 catalytic cysteine (Cys-cap loop) prevented a close 
packing between UbcH10 and the ternary complex. Accordingly, the protein-
protein interface was refined by means of SMD simulations, which were set 
up using Amber 12. To this end, the Cys-cap loop (residues 801–825) was 
deleted and capping groups were added to the newly formed terminals. The 
distance between the sulphur atom of the UbcH10 catalytic cysteine (C114) 
and the carbon atom of the terminal carboxyl group of Ub(T) was constrained 
to 3 Å in 4 steps: i) from the initial distance (9.4 Å) to 7 Å in 0.5 ns with a 
force constant of 5 kcal/mol; ii) from 7 to 4 Å in 1.5 ns with a force constant 
of 5 kcal/mol; iii) from 4 to 3 Å in 2 ns with a force constant of 10 kcal/mol; 
iv) and finally from 3 to 2.5 Å in 4 ns with a force constant of 20 kcal/mol. At 
the end, the system was rebuilt by adding the removed Cys-cap loop (UbA1 
residues 801–825), equilibrated with suitable constraints in order to relax the 
residues in the Cys-cap loop, and finally subjected to an unrestrained MD (50 
ns) simulation. 
7.7.6 Binding free energy evaluation and virtual alanine scanning 
Binding free energies of the docking solutions and sampled in MD 
simulations were estimated using the SIE method, as described in §3.3.2. The 
contribution of specific residues to the binding between interacting proteins 
was examined by using alanine scanning [126, 127]. 
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8. Structural studies of small Peptide Nucleic Acid, a new 
inhibitor of miR-509-3p involved in the regulation of 
Cystic Fibrosis Disease-Gene expression 
The work discussed in this chapter has been published in a peer-reviewed 
journal article [128] and it is the result of an interdisciplinary collaboration. F. 
Amato, R. Tomaiuolo, A. Elce and G. Castaldo performed biological 
experiments; F. Nici, S. D’Errico, N. Borbone, G. Piccialli and G. Oliviero 
performed the PNA synthesis; G. De Rosa and L. Mayol provided technology 
for cell penetration; C. M. Morgillo and B. Catalanotti performed 
computational calculations. 
 
8.1 Introduction 
A number of human diseases have been associated with a deregulation of 
specific microRNAs (miRNAs) [129–134]. Among these is the genetic 
disease Cystic Fibrosis (CF). CF is the most common lethal genetic disorder 
among Caucasians with one in every 3,000 new-borns affected. CF is due to 
mutations in the CFTR gene encoding the CFTR chloride channel expressed 
by most epithelial cells [135]. The CF phenotype typically includes the altered 
sweat test, pancreatic insufficiency, and pulmonary infections that gradually 
lead to respiratory insufficiency. To date more than 1,900 mutations of CF 
gene have been described, and a set of miRNAs inhibiting the CFTR 
expression at the posttranscriptional level has been described [136]. 
Furthermore, the group of Prof. G. Castaldo and Prof. G. Oliviero has shown 
that mutations in the 3′UTR of the CFTR gene may have a pathogenic effect 
by enhancing the affinity for the miR-509-3p miRNA [137]. 
The approaches to downregulate a specific miRNA essentially use 
oligonucleotide (ON) analogues which being complementary to miRNAs are 
able to reduce or inhibit their activity. Recently, several studies have 
demonstrated that the DNA mimics named peptide nucleic acids (PNAs) can 
be effectively used as anti-miRNA [138-140]. In the PNAs a 2-aminoethyl-
glycine polymer replaces the ribose-phosphate DNA backbone [141]. PNA 
molecules are resistant to protease and nuclease degradation and recognize 
with a high affinity complementary fragments of DNA or RNA [142]. Many 
studies have been performed on the binding capability of PNAs and on the 
topological way in which they can recognize nucleic acids in single strand, 
duplex, or quadruplex arrangements to form heteroduplex, heterotriplex, and 
heteroquadruplex complexes [143-147] or to act as quadruplex ligands, 
respectively [148, 149]. The anti-miRNA activity of a PNA can occur in the 
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nucleus by targeting the pre-miRNA or in the cytoplasm by binding the pre-
miRNA and/or the mature miRNA [150]. In both cases, it is necessary that the 
PNA can pass through the cell membrane and through the nuclear membrane 
for the former case. The main drawback in the use of PNAs as intracellular 
probes lies in the poor water solubility when their length exceeds the 12–14 
bases. Furthermore, the cellular uptake behaviour of a PNA is not easily 
predictable because it is mostly dependent on the PNA base composition and 
the overall lipophilicity. Recent studies report on the feasibility of a miRNA 
regulation approach by using unmodified PNAs and PNAs conjugated with 
peptides or hydrophilic groups [151, 152]. 
The group of Prof. Oliviero (Department of Pharmacy, University of Naples) 
synthesized a 14-base long PNA fully complementary to the 5′-end of miR-
509-3p and carrying a tetrapeptide tail containing two serine phosphates at its 
C-terminus and a fluorescein group at its N-terminus (PNA1, Table 22). They 
demonstrated, by in vitro studies on A549 cell lines, that the serine phosphate 
tail represents a suitable conjugation to improve both the water solubility and 
the cellular uptake of a PNA molecule. Furthermore, they have demonstrated 
that PNA1 is able to recognize miR-509-3p in A549 cells by reverting the 
expression of the luciferase gene containing the 3′UTR of the CFTR gene.  
 
Table 22: Structures and sequences of miR-509-3p and PNA1–3. PNA sequences are written 
from C- to N-terminus. 
 
Synthesis of longer PNAs (14–16 bases long) is an expensive and not an 
easily achievable task, especially when the PNA is conjugated to peptide tails 
and/or labelled at both ends. In addition, a recent study has reported that a 
very short LNA (8 bases long) was able to recognize and silence a family of 
miRNAs with no off-target effects [153]. Furthermore, experimental and 
computational evidence for different types of miRNA target sites 
demonstrated that probes with as few as seven base pairs of complementarity 
to the 5′-end of miRNAs are sufficient to confer regulation in vivo and are 
used in biologically relevant targets [154, 155]. The synthesis of PNA2 was 
preceded by a molecular modelling study aimed at evaluating the structural 
behaviour of the goal seven bases long miR-509-3p/PNA2 heteroduplex in 
comparison with that of the longer miR-509-3p/PNA1 heteroduplex. The 
stability and the structure of the miR-509-3p/PNA2 duplex were evaluated by 
molecular modelling and by UV, CD, and EMSA analyses. Based on these 
analyses, PNA2, notwithstanding its reduced length, was still able to 
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recognize miR-509-3p in A549 cells where it reverted the expression of the 
luciferase gene containing the 3′UTR of the CFTR gene. 
 
8.2 MD simulations of the heteroduplex miR-509-3p/PNA1 and miR-
509-3p/PNA2 
The miR-509-3p/PNA2 and miR-509-3p/PNA1 heteroduplexes were built 
starting from the NMR structure of the RNA(GAGUUC)/PNA(GAACTC) 
duplex (PDB ID: 176D) [156] as described in Materials and Methods. Each 
system was firstly analysed by means of three runs of 20 ns molecular 
dynamics in order to better sample the conformational behaviour of the 
complexes. Secondly, in order to further assay the stability of the miR-509-
3p/PNA2 duplex, we extended one run of miR-509-3p/PNA2 up to 50 ns, for 
a total simulation time of 90 ns for miR-509-3p/PNA2 and 60 ns for miR-509-
3p/PNA1. 
The macroscopic properties of the systems, such as temperature, pressure, 
volume, density, and energy, were fairly constant during the whole simulation 
for both of the systems (data not shown). As expected, the analysis of the 
RMSD in the trajectories of miR-509-3p/PNA2 and miR-509-3p/PNA1 
complexes showed high flexibility of the single stranded miRNA segment 
(Fig. 60). On the contrary, the behaviour of the region of miR-509-3p 
hybridized with PNAs was characterized by low RMSD values and low 
fluctuations, thus indicating the presence of a stable secondary structure 
(Fig. 60). 
 
Fig. 60: Root-mean-square deviation in the three MD runs on miR-509-3p/PNA2 (a) and miR-
509-3p/PNA1 (b) heteroduplexes. Superimpositions were made on the MD-averaged structures 
for each trajectory taking into account the whole structure (blue, orange, and purple) or only the 
duplex region (black, red, and green). 
 
Moreover, the comparison of the average structures obtained from each 
trajectory (Fig. 61) revealed the convergence of the trajectories as shown by 
the low RMSD values in the duplex region of both complexes with PNA1 and 
PNA2 (>0.5 Å and >0.9 Å, respectively). 
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Fig. 61: Superimposition of the MD average structures of miR-509-3p/PNA1 complex (a) and 
of miR-509-3p/PNA2 complex (b). Duplexes regions are represented in liquorice coloured by 
atom type (carbon in cyan, oxygen in red, nitrogen in blue, phosphate in brown, and hydrogen 
in white). The miR-509-3p single strand regions are represented in spheres coloured by MD run 
(blue, run 1; green, run 2; red, run 3). (c) RMSD in Å, calculated on phosphates in the duplexes 
regions, among the average structures of the MD runs. 
 
The analysis of the helicoidal parameters and torsion angles (Table 22) 
demonstrated that both miRNA/PNA duplexes could be described as A-type 
double helix with few noticeable deviations from the canonical structure. In 
particular, the lower step-averaged twist values reported in Table 22 indicated 
a slight unwinding of the RNA/PNA helices with respect to canonical A-RNA 
structures, in agreement with what was previously observed in other MD 
simulations of RNA/PNA duplexes [157, 158]. The lower roll and tilt values 
observed in the MD run pointed at an expansion of the major groove. Finally, 
the analysis of torsion angles reported in Table 22 highlighted the strong 
similarity between the two duplexes.  
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Table 22: Comparison of backbone torsion angles and helicoidal parameters for average 
structures of each run after 20 ns MD simulation. Values for structure obtained by averaging all 
the three runs are reported in bold. Standard deviation is reported in brackets. 
 
Taken together, the MD results indicated that both heteroduplexes assumed a 
conformation resembling the canonical A-type RNA helix rather than the 
experimentally determined NMR structure. Moreover, the torsion angles of 
RNA segments in miR-509-3p/PNA2 and miR-509-3p/PNA1 duplexes 
showed values very similar to those adopted by miR20a in the 4F3T crystal 
structure [159] suggesting that PNA2 and PNA1 could easily interact with the 
AGO-miRNA complex, not requiring any conformational adaptations. On the 
basis of the positive indications coming from the MD studies, the PNA2 
molecule were synthesised and was demonstrated its ability to recognize the 
2′-OMe mimic of miR-509-3p by CD, UV, and EMSA studies and to restore 
the expression of the luciferase gene containing the 3′UTR of the CFTR gene 
in the presence of miR-509-3p. 
 
8.3 Experimental section 
The initial structures of the heteroduplexes formed by miR-509-3p with 
PNA1 and PNA2 were built by using the NMR structure of the 6-mer 
RNA(GAGUUC)/PNA(GAACTC) heteroduplex (PDB ID = 176D) [157]. 
Starting from the lowest energy NMR structure, one nucleotide was added 
aligning a duplicate of the reference structure on the PNA backbone. Once the 
7-mer heteroduplex was obtained, the bases were mutated to match the PNA2 
sequence. Watson-Crick canonical pairs were then refined using distance 
restraints on the first seven bases of miR-509-3p/PNA2 heteroduplex. The 
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same procedure was used to build the miR-509-3p/PNA1 heteroduplex, 
starting from the refined structure of miR509-3P/PNA2 heteroduplex. 
The equilibration of the systems and production of MD simulations were 
performed using the Amber 12 suite of programs [62]. The Leap module of 
Ambertools13 was used to create parameter and topology files for the MD 
simulations using the ff99SB force field for RNA and standard amino acids 
[160]. For PNAs parameterization we used the Sanders et al. force field for 
PNA [161] downloaded from the RESP and ESP charge database (R.E.DD.B. 
http://q4md-forcefieldtools.org/REDDB Project ID = F93) [162], whereas the 
parameters for serine phosphate were taken from reference [163]. TIP3P 
water molecules were added with a minimum spacing of 10.0 Å from the box 
edges to the RNA:PNA molecules and Na+ counterions were added to each 
system to reach the neutralization of the system. 
The geometry of the system was minimized, equilibrated and subjected to MD 
production following the general procedure described in §3.2 During 
thermalization, interstrand distance restraints were applied to the RNA:PNA 
heteroduplex to preserve all base pairs canonical Watson-Crick bond, 
allowing 0.1 Å movement from the equilibrium bond distance (either closer or 
farther). Thus, the force constant applied during thermalization was set to 
32  kcal/mol·Å2 and was gradually reduced in the next step to 10  kcal/mol·Å2 
and subsequently decreased by increments of 5 kcal/mol·Å2 in the next stages.  
All production simulations were repeated in triplicate with random seeding 
for initial velocities and extended to 20 ns. In order to further assay the 
stability of the RNA:PNA heteroduplexes, we extended one run of PNA2 up 
to 50 ns, for a total simulation time of 90 ns for PNA2 and 60 ns for PNA1. 
The structural features were determined using the Curves+ software package 
[164], and visualization of trajectories was performed in VMD [165], while 
the trajectory analyses were performed using Ambertools13. 
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9. Conclusions 
 
In this study we reported computational studies of the binding mode of the 
flurbiprofen and ibuprofen amide derivatives (Flu-AM1 and Ibu-AM5) as 
mean for the rational design of new potent FAAH/COX dual inhibitors. In 
order to investigate the binding mode of such compounds, a computational 
approach consisting of molecular docking, MD simulations and free energy 
evaluation of the ligand-receptor complexes has been applied. The molecular 
modelling studies point out the binding mode of the enantiomers of Ibu-AM5 
and Flu-AM1 into the substrate access channel of FAAH supported by 
mutagenesis studies. Indeed, our results showed the formation of a stable 
hydrogen bond between the carbonyl amide moiety and the sidechain of 
Thr488, and enzymatic assays revealed lower activity of (R)-Flu-AM1 against 
the FAAHT488A mutated variant. Given the potentially useful properties of 
compounds with combined FAAH/COX inhibitory properties, the 
characterisation of the binding mode of Ibu-AM5 and Flu-AM1 into the 
substrate access channel of FAAH provided information for the design of new 
derivatives. The substitution of the isobutyl group of Ibu-AM5 with (2-
(trifluoromethyl)pyridin-4-yl)amino group led to the design of TPA5 
derivative, showing a comparable activity (IC50 = 0.59 µM) with the lead 
(Ibu-AM5, IC50 = 0.52 µM). Kinetic studies of TPA5 revealed that it is a pure 
competitive inhibitor of rFAAH. Computational studies, exploiting QM/MM 
and free energies approaches, allowed us to identify a putative binding mode 
for TPA5, overlapping the anandamide analogue MAFP and strictly 
resembling the binding mode of α-ketoheterocycles, competitive FAAH 
inhibitors. A number of TPA5 derivatives have been designed and tested. 
Among them, the compound TPA27 exhibited a 10-fold enhancement in the 
inhibitory profile against FAAH (IC50 = 0.058 µM). Kinetics studies showed 
that TPA27, unlike TPA5, behaves as non-competitive inhibitor with Ki and 
alpha values of 0.28 µM and 1.03, respectively. Thermodynamic Integration 
focussing on the transformation of TPA5 in TPA27 yielded a free energy 
difference of 0.3 kcal/mol demonstrating a remarkable lower affinity of 
TPA27 with respect to TPA5, in the competitive binding site. Moreover, 
incubation and time-dependency experiments demonstrated that TPA27 is a 
reversible inhibitor and cannot be considered as tight inhibitor. Taking 
together these results highlighted that TPA27 can be considered the first non-
competitive reversible FAAH inhibitor reported so far, and that it more likely 
binds to an allosteric site.  
Enzymatic and kinetics assays carried on mFAAH highlighted differences in 
the inhibitory potency against rat and mouse FAAH, for all the compounds 
studied. In particular, we observed a weakening in the inhibition against 
mFAAH, regardless the inhibition mechanism, suggesting a different 
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aminoacid composition of both competitive and non-competitive binding site. 
Hence, the differences in the sequence of rat and mouse FAAH, were used as 
criteria in the analysis of the binding site search. A putative allosteric site was 
found between the CP and the interface of the monomers. Computational 
studies in the allosteric site allowed the definition of the binding mode of Ibu-
AM5 and TPA27, but not of Flu-AM1. Nevertheless, we designed a series of 
derivatives of Ibu-AM5 and Flu-AM1, in order to get more information on the 
SAR leading to the identification of derivatives with improved activity against 
FAAH (Ibu-AM56, IC50 = 0.08 µM; Ibu-AM57, IC50 = 0.1 µM; Flu-AM3, 
IC50 = 0.02 µM).  
Results confirmed the agreement of the SAR of Ibu-AM derivatives with the 
selected binding mode for Ibu-AM5, but could not give useful information 
about the non-competitive binding mode of Flu-AM1.   
However, kinetic experiments highlighted how small substitutions in the 
compounds, should dramatically affect the inhibition mechanism and binding 
preferences of these inhibitors. In light of such considerations, caution should 
be taken in order to derive the SAR, since apparently minor structural 
modifications could influence not only the binding mode, but also the 
inhibition mechanism.   
Moreover, working on two side projects were designed potential anticancer 
peptides that interfere in the formation of the tetrameric complex 
hUbA1/UbcH10/Ub2 and structural studies on the inhibition of miR-509-3p, 
involved in the regulation of CF, by PNA strands of various length was 
pursued. 
 
 
 103 
 
 
Bibliography 
1. Scarpelli R, Sasso O, Piomelli D. A Double Whammy: Targeting Both 
Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To 
Treat Pain and Inflammation. 
2. Rouzer CA, Marnett LJ. Endocannabinoid Oxygenation by 
Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk 
between the Eicosanoid and Endocannabinoid Signaling Pathways. Chem 
Rev. 2011 Oct 12; 111(10): 5899–5921. 
3. Axelrod J, Felder CC. Cannabinoid receptors and their endogenous 
agonist, anandamide. Neurochem Res. 1998 May;23(5):575-81. 
4. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, 
Battistini L, Maccarrone M. Anandamide suppresses proliferation and 
cytokine release from primary human T-lymphocytes mainly via CB2 
receptors. PLoS One 2010 Jan 14;5(1):e8688. 
5. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient 
receptor potential (TRP) channels: A further opportunity to develop new 
endocannabinoid-based therapeutic drugs. Curr Med Chem. 
2010;17(14):1430-49. 
6. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca 
F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. 
Oleylethanolamide regulates feeding and body weight through activation 
of the nuclear receptor PPAR-alpha. Nature 2003 Sep 4;425(6953):90-3. 
7. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate 
endocannabinoid signaling in the nervous system. Chem Rev. 2008 
May;105(5):1687-707. 
8. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. 
Molecular characterization of an enzyme that degrades neuromodulatory 
fatty-acid amides. Nature 1996 Nov 7;384(6604):83-7. 
9. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, 
Takayama H, Waku K, Seki C, Baba N, Ishima Y. Evidence that the 
cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-
activity relationship of 2-arachidonoylglycerol, ether-linked analogues, 
and related compounds. J Biol Chem. 1999; 274(5):2794–801. 
10. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, 
Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Sharkey KA. 
Targeting endocannabinoid degradation protects against experimental 
colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med. 
2008;86:925–936. 
11. Blobaum AL, Marnett LJ. Structural and functional basis of 
cyclooxygenase inhibition. J Med Chem. 2007 Apr 5;50(7):1425-41. 
12. Iñiguez MA, Cacheiro-Llaguno C, Cuesta N, Diaz-Munoz MD, Fresno M. 
Prostanoid function and cardiovascular disease. Arch Physiol Biochem. 
2008;114:201–9. 
13. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into 
COX-2 biology and inhibition. Brain Res Rev. 2005 Apr;48(2):352-9. 
14. Ghilardi JR, Svensson CI, Rogers SD, Yaksh TL, Mantyh PW. 
Constitutive spinal cyclooxygenase-2 participates in the initiation of 
 104 
 
tissue injury-induced hyperalgesia. J Neurosci 2004 Mar 17;24(11):2727-
32. 
15. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide 
from anandamide by cyclooxygenase-2. J Biol Chem 1997 Aug 
22;272(34):21181-6. 
16. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, 
Ellington HC. Pharmacological characterization of the anandamide 
cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol 
Exp Ther. 2002 Jun;301(3):900-7. 
17. World Health Organization (Ed.), Cancer pain relief: with a guide to 
opioid availability, second Ed., World Health Organization, Geneva, 
1996. 
18. Meade EA, Smith W L, DeWitt D L. J. Biol. Chem. 199;, 268:6610. 
19. Wallace, JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why 
doesn't the stomach digest itself? Physiol Rev. 2008; 88:1547–65. 
20. Naidu P, Booker L, Cravatt B, Lichtman A. Synergy between enzyme 
inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral 
nociception. J Pharmacol Exp Ther. 2009; 329:48–56. 
21. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, 
Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, 
Calignano A, Mor M, Tarzia G, Piomelli D. Anandamide suppress pain 
initiation through a peripheral endocannabinoid mechanism. Nat. 
Neurosci. 2010; 13:1265. 
22. Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, Armirotti, 
A, Moreno-Sanz G, Reggiani A, Piomelli D. Peripheral FAAH inhibition 
causes profound antinociception and protects againstindo methacin-
induced gastric lesions. Pharmacol. Res. 2012; 65:553. 
23. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient 
randomised, placebo-controlled clinical trial with the irreversible fatty 
acid amide hydrolase-1 inhibitor PF-04457845, which modulates 
endocannabinoids but fails to induce effective analgesia in patients with 
pain due to osteoarthritis of the knee. Pain 153, 1837–46. 
24. Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, Di 
Marzo V. Discovery of prostamide F2α and its role in inflammatory pain 
and dorsal horn nociceptive neuron hyperexcitability. PLoS ONE 7, 
e31111. 
25. Cipriano M, Bjorklund E, Wilson AA, Congiu C, Onnis V, Fowler CJ. 
Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-
methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. Eur J 
Pharmacol. 2013; 720:383–90. 
26. Cocco MT, Congiu C, Onnis V, Morelli M, Cauli O. Synthesis of 
ibuprofen heterocyclic amides and investigation of their analgesic and 
toxicological properties. Eur J Med Chem. 2003; 38:513–8. 
27. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug 
discovery paradigm. J Med Chem. 2005; 48:6523–43. 
28. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development 
of novel analgesic agents targeting both fatty acid amide hydrolase and 
either cyclooxygenase or TRPV1. Br J Pharmacol. 2009 Feb; 156(3):412-
9. 
29. Chebrou H, Bigey F, Arnaud A, Galzy P. Study of the amidase signature 
group. Biochim Biophys Acta 1996; 1298:285–93. 
 105 
 
30. McKinney MK, Cravatt BF. Structure and function of fatty acid amide 
hydrolase. Annu Rev Biochem 2005; 74:411–32. 
31. Patricelli MP, Lovato MA, Cravatt BF. Chemical and mutagenic 
investigations of fatty acid amide hydrolase: evidence for a family of 
serine hydrolases with distinct catalytic properties. Biochemistry 1999 
Aug 3; 38(31):9804-12 
32. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural 
adaptations in a membrane enzyme that terminates endocannabinoid 
signaling. Science. 2002 Nov 29; 298(5599):1793-6. 
33. Cravatt BF, Lichtman AH. Fatty Acid Amide Hydrolase: an emerging 
therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 
2003; 7:469-75. 
34. Kage KL, Richardson PL, Traphagen L, Severin J, Pereda-Lopez A, 
Lubben T, Davis-Taber R, Vos MH, Bartley D, Walker K, Harlan J, 
Solomon L, Warrior U, Holzmann TF, Faltynek C, Surowy CS, Scott VE. 
A high throughput fluorescent assay for measuring the activity of fatty 
acid amide hydrolase. J Neurosci Methods 2007; 161: 47–54. 
35. http://crdd.osdd.net/oscadd/ketodrug/ 
36. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid 
amide hydrolase (FAAH) inhibitors. J Med Chem. 2008; 51:7327-43. 
37. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second 
fatty acid amide hydrolase with variable distribution among placental 
mammals. J Biol Chem. 2006; 281:36569–78. 
38. Mileni M, Johnson DS, Wang Z, Everdeen DS, Liimatta M, Pabst B, 
Bhattacharya K, Nugent RA, Kamtekar S, Cravatt BF, Ahn K, Stevens 
RC. Structure-guided inhibitor design for human FAAH by interspecies 
active site conversion. Proc Nat. Acad Sci USA 2008; 105:12820-4. 
39. Bertolacci L, Romeo E, Veronesi M, Magotti P, Albani C, Dionisi M, 
Lambruschini C, Scarpelli R, Cavalli A, De Vivo M, Piomelli D, Garau 
G. A binding site for non-steroidal anti-inflammatory drugs in FAAH. J 
Am Chem Soc. 2013 Jan 9; 135(1): 22–5. 
40. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, 
Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, 
Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, 
Stevens RC, Cravatt BF. Discovery and characterization of a highly 
selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 
2009; 16:411-20. 
41. Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens 
RC. Binding and inactivation mechanism of a humanized fatty acid amide 
hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal 
structures. J Am Chem Soc. 2009; 131:10497-506. 
42. Mileni M, Garfunkle J, Ezzili C, Kimball FS, Cravatt BF, Stevens RC, 
Boger DL. X-ray crystallographic analysis of alpha-ketoheterocycle 
inhibitors bound to a humanized variant of fatty acid amide hydrolase. J 
Med Chem. 2010; 53:230-40. 
43. Mileni M, Kamtekar S, Wood DC, Benson TE, Cravatt BF, Stevens RC. 
Crystal structure of fatty acid amide hydrolase bound to the carbamate 
inhibitor URB597: discovery of a deacylating water molecule and insight 
into enzyme inactivation. J Mol Biol. 2010; 400:743-54. 
44. Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H, Lindstrom 
M, Xu G, Uyeda C, Ma Z, Li Y, Kayser F, Walker NP, Wang Z. 
 106 
 
Discovery and molecular basis of potent noncovalent inhibitors of fatty 
acid amide hydrolase (FAAH). Proc Natl Acad Sci USA 2011; 108:7379-
84. 
45. Ezzili C, Mileni M, McGlinchey N, Long JZ, Kinsey SG, Hochstatter DG, 
Stevens RC, Lichtman AH, Cravatt BF, Bilsky EJ, Boger DL. Reversible 
competitive alpha-ketoheterocycle inhibitors of fatty acid amide 
hydrolase containing additional conformational constraints in the acyl 
side chain: orally active, long-acting analgesics. J Med Chem. 2011; 
54:2805-22. 
46. Otrubova K, Brown M, McCormick MS, Han GW, O'Neal ST, Cravatt BF, 
Stevens RC, Lichtman AH, Boger DL. Rational design of fatty acid 
amide hydrolase inhibitors that act by covalently bonding to two active 
site residues. J Am Chem Soc. 2013; 135:6289-99. 
47. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, 
Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, 
Cuomo V, Piomelli D. Modulation of anxiety through blockade of 
anandamide hydrolysis. Nat Med. 2003; 9:76-81. 
48. Tarzia G1, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Plazzi PV, 
Park C, Kathuria S, Piomelli D. Design, synthesis, and structure-activity 
relationships of alkylcarbamic acid aryl esters, a new class of fatty acid 
amide hydrolase inhibitors. J Med. Chem. 2003; 46:2352-60. 
49. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, 
Piersanti G, Kathuria S, Piomelli D. Cyclohexylcarbamic acid 3'- or 4'- 
substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: 
synthesis, quantitative structure-activity relationships, and molecular 
modelling studies. J Med Chem. 2004; 47:4998-5008. 
50. Lodola A, Capoferri L, Rivara S, Chudyk E, Sirirak J, Dyguda-
Kazimierowicz E, Andrzej Sokalski W, Mileni M, Tarzia G, Piomelli D, 
Mor M, Mulholland AJ. Understanding the role of carbamate reactivity in 
fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. 
Chem Commun (Camb). 2011; 47:2517-9. 
51. Lodola A, Mor M, Rivara S, Christov C, Tarzia G, Piomelli D, Mulholland 
AJ. Identification of productive inhibitor binding orientation in fatty acid 
amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem 
Commun (Camb). 2008; 2:214-6. 
52. Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J, Webb 
M, Karbarz MJ, Brown S, Wilson S, Scott B, Tham CS, Luo L, Palmer J, 
Wennerholm M, Chaplan S, Breitenbucher JG. Thiadiazolopiperazinyl 
ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 
2008; 18:4338-43. 
53. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, 
Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF. Novel 
mechanistic class of fatty acid amide hydrolase inhibitors with remarkable 
selectivity. Biochemistry 2007; 46:13019-30. 
54. Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, 
Barrett DA, Kendall DA, Bennett AJ, Chapman V. Lack of effect of 
chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory 
pain behaviour: evidence for plastic changes in the endocannabinoid 
system. Br J Pharmacol. 2012; 167:627–40. 
 107 
 
55. Alhouayek M, Muccioli GG. COX-2-derived endocannabinoid metabolites 
as novel inflammatory mediators. Trends Pharmacol Sci. 2014 
Jun;35(6):284-92. 
56. Fowler CJ, Janson U, Johnson RM, Wahlström G, Stenström A, Norström 
K, Tiger G. Inhibition of anandamide hydrolysis by the enantiomers of 
ibuprofen, ketorolac and flurbiprofen Arch Biochem Biophys. 1999; 
362(2):191-6. 
57. Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, 
Dionisi M, Tarozzo G, Piomelli D, Cavalli A, De Vivo M. Identification 
and characterization of carprofen as a multitarget fatty acid amide 
hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012; 55(20):8807-26. 
58. Fowler CJ, Bjorklund E, Lichtman AH, Naidu PS, Congiu C, Onnis V. 
Inhibitory properties of ibuprofen and its amide analogues towards the 
hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J 
Enzyme Inhib Med Chem. 2013; 28:172–82. 
59. Sasso O, Migliore M, Habrant D, Armirotti A, Albani C, Summa M, 
Moreno-Sanz G, Scarpelli R, Piomelli D. Multitarget fatty acid amide 
hydrolase/cyclooxygenase blockade suppresses intestinal inflammation 
and protects against nonsteroidal anti-inflammatory drug-dependent 
gastrointestinal damage. FASEB J. 2015 Jun;29(6):2616-27 
60. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, 
Olson AJ. Autodock4 and AutoDockTools4: automated docking with 
selective receptor flexiblity. J Comput Chem. 2009; 16:2785–91. 
61. Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, 
Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, 
Connors R, Wang Z, Kayser F. Identification of potent, noncovalent fatty 
acid amide hydrolase (FAAH) inhibitors. Bioorg Med Chem Lett 2011; 
21:2492-6. 
62. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke 
RE, et al. AMBER 12, University of California, San Francisco, 2012. 
63. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, 
et al. Improved side-chain torsion potentials for the Amber ff99SB protein 
force field. Proteins. 2010; 78:1950–8. 
64. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development 
and testing of a general amber force field. J Comput Chem. 2004; 
25:1157–74. 
65. Bayly CI, Cieplak P, Cornell WD, Kollman PA. A well-behaved 
electrostatic potential based method using charge restraints for deriving 
atomic charges J Phys Chem. 1993; 97:10269–80. 
66. Gaussian 09, Revision D.01, Frisch MJ, Trucks GW, Schlegel HB, 
Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian, Inc., Wallingford 
CT, USA, 2009. 
67. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the 
MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free 
energy calculations based on molecular dynamics simulations. J Chem Inf 
Model. 2011; 51: 69–82. 
68. Miller BR 3rd, McGee TD Jr., Swails JM, Homeyer N, Gohlke H, 
Roitberg AE. MMPBSA.py: An Efficient Program for End-State Free 
Energy Calculations. J Chem Theory Comput. 2012; 8: 3314–3321. 
 108 
 
69. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development 
and testing of a general amber force field. J Comput Chem. 2004; 25: 
1157–74. 
70. Naïm M, Bhat S, Rankin KN, Dennis S, Chowdhury SF, et al. Solvated 
interaction energy (SIE) for scoring protein-ligand binding affinities. 1. 
Exploring the parameter space. J Chem Inf Model 2007; 47:122–33. 
71. Chan SL and Purisima EO. Molecular surface generation using marching 
tetrahedra. J Comput Chem. 1998; 19:1268–77. 
72. Purisima EO, Nilar SH. A simple yet accurate boundary element method 
for continuum dielectric calculations. J Comput Chem. 1995; 16:681–9. 
73. Steinbrecher T, Joung I, Case DA. Soft-core potentials in thermodynamic 
integration: comparing one- and two-step transformations. J Comput 
Chem. 2011; 32(15):3253-63. 
74. Amber 14. Reference manual. http://ambermd.org/doc12/Amber14.pdf 
75. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. 
SWISS-MODEL: modelling protein tertiary and quaternary structure 
using evolutionary information. Nucleic Acids Res. 2014;42:W252–8. 
76. Myllymäki MJ, Käsnänen H, Kataja AO, Lahtela-Kakkonen M, Saario 
SM, Poso A, et al. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl 
alkylcarbamates as novel FAAH inhibitors: Insight into FAAH 
enantioselectivity by molecular docking and interaction fields. Eur J Med 
Chem. 2009;44:4179–91 
77. Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, et 
al. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral 
azetidine ureas. Bioorg Med Chem Lett. 2009;19:4241–4. 
78. Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, et 
al. Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J 
Med Chem. 2013;56:8484–96. 
79. Karlsson J, Morgillo CM, Deplano A, Smaldone G, Pedone E, Luque FJ, 
Svensson M, Novellino E, Congiu C, Onnis V, Catalanotti B, Fowler CJ. 
Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of 
Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and 
Binding Mode. PLoS One. 2015 Nov 13;10(11):e0142711 
80. Segel IH (1975). Enzyme kinetics. Behavior and analysis of rapid 
equilibrium and steady-state enzyme systems. John Wiley & Sons, New 
York. 
81. Knight JL, Brooks CL 3rd. Lambda-dynamics free energy simulation 
methods. J Comput Chem. 2009 Aug;30(11):1692-700. 
82. Blat Y. Non-competitive inhibition by active site binders. Chem Biol Drug 
Des. 2010;75:535-40. 
83. Rome LH, Lands WEM. Structural requirements for time-dependent 
inhibition of prostaglandin biosynthesis bu anti-inflammatory drugs. Proc 
Natl Acad Sci USA. 1975;72:4863-5. 
84. Porter CT, Bartlett GJ, Thornton JM: The Catalytic Site Atlas: a resource 
of catalytic sites and residues identified in enzymes using structural data. 
Nucleic Acids Res 2004, 32(Database issue):D129-D133. 
85. Mistry J, Bateman A, Finn RD: Predicting active site residue annotations 
in the Pfam database. BMC Bioinformatics 2007, 8: 298. 
86. Goodey NM, Benkovic SJ: Allosteric regulation and catalysis emerge via a 
common route. Nat Chem Biol 2008, 4(8):474–482. 
 109 
 
87. Panjkovich A, Daura X: Assessing the structural conservation of protein 
pockets to study functional and allosteric sites: implications for drug 
discovery. BMC Struct Biol 2010, 10: 9. 
88. Le Guilloux V, Schmidtke P, Tuffery P, Fpocket: An open source platform 
for ligand pocket detection. BMC Bioinformatics 2009, 10:168. 
89. Rape M, Kirschner MW. Autonomous regulation of the anaphase-
promoting complex couples mitosis to S-phase entry. Nature 2004; 
432:588–95. 
90. De Gramont A, Ganier O, Cohen-Fix O. Before and after the spindle 
assembly checkpoint—an APC/C point of view. Cell Cycle 2006; 5: 
2168–71. 
91. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, et al. 
UbcH10 overexpression may represent a marker of anaplastic thyroid 
carcinomas. Br J Cancer 2005; 93:464–71. 
92. Fujita T, Liu W, Doihara H, Date H, Wan Y. Dissection of the APCCdh1-
Skp2 cascade in breast cancer. Clin Cancer Res. 2008; 14:1966–75. 
93. Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, et al. UbcH10 
expression may be a useful tool in the prognosis of ovarian carcinomas. 
Oncogene 26:2136–40. 
94. Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F, et al. 
Analysis of UbcH10 expression represents a useful tool for the diagnosis 
and therapy of astrocytic tumors. Clin Neuropathol. 2008; 27:219–23. 
95. Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, et al. 
UbcH10 expression in human lymphomas. Histopathology 2009; 54:731–
40. 
96. Haas AL, Warms JV, Hershko A, Rose IA. Ubiquitin-activating enzyme. 
Mechanism and role in protein-ubiquitin conjugation. J Biol Chem. 1982; 
257:2543–48. 
97. Kleiger G, Mayor T. Perilous journey: a tour of the ubiquitin-proteasome 
system. Trends Cell Biol. 2014; 24:352–59.  
98. Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems for ubiquitin 
differentially regulate E2 enzyme charging. Nature 2007; 447:1135–8. 
99. Fang S, Weissman AM. A field guide to ubiquitylation. Cell Mol Life Sci. 
2004 61:1546–61. 
100. Correale S, de Paola I, Morgillo CM, Federico A, Zaccaro L, Pallante P, 
Galeone A, Fusco A, Pedone E, Luque FJ, Catalanotti B. Structural model 
of the hUbA1-UbcH10 quaternary complex: in silico and experimental 
analysis of the protein-protein interactions between E1, E2 and ubiquitin. 
PLoS One. 2014 Nov 6;9(11):e112082. 
101. de Vries SJ, van Dijk M, Bonvin AM. The HADDOCK web server for 
data-driven biomolecular docking. Nat Protoc. 2010; 5:883–97. 
102. Lyskov S, Gray JJ. The RosettaDock server for local protein-protein 
docking. Nuc Acids Res. 2008; 36:W233–W238. 
103. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from 
structures to functions. Nat Rev Mol Cell Biol. 2009; 10:659–71. 
104. Schäfer A, Kuhn M, Schindelin H. Structure of the ubiquitin-activating 
enzyme loaded with two ubiquitin molecules. Acta Cryst. 2014; D70, 
1311–20. 
105. Huang DT, Hunt HW, Zhuang M, Ohi MD, Holton JM, et al. Basis for a 
ubiquitin-like protein thioester switch toggling E1–E2 affinity. Nature 
2007; 445:394–8. 
 110 
 
106. Tokgöz Z, Siepmann TJ, Streich F Jr, Kumar B, Klein JM, et al. E1–E2 
interactions in ubiquitin and Nedd8 ligation pathways. J Biol Chem. 
2012; 287:15512–22. 
107. Pitluk ZW, McDonough M, Sangan P, Gonda DK. Novel CDC34 (UBC3) 
ubiquitin-conjugating enzyme mutants obtained by charge-to-alanine 
scanning mutagenesis. Mol Cell Biol. 1995; 15: 1210–1219.  
108. Sullivan ML, Vierstra RD. Cloning of a 16-kDa ubiquitin carrier protein 
from wheat and Arabidopsis thaliana. Identification of functional domains 
by in vitro mutagenesis. J Biol Chem. 1991; 266:23878–85. 
109. Bencsath KP, Podgorski MS, Pagala VR, Slaughter CA, Schulman BA 
(2002) Identification of a multifunctional binding site on ubc9p required 
for smt3p conjugation. J Biol Chem. 2002; 277: 7938–45. 
110. Poornam G, Matsumoto A, Ishida H, Hayward S. A method for the 
analysis of domain movements in large biomolecular complexes. Proteins 
2009; 76:201–21. 
111. Szczepanowski RH, Filipek R, Bochtler M (2005) Crystal structure of a 
fragment of mouse ubiquitin-activating enzyme. J Biol Chem. 2005; 
280:22006–11. 
112. Lee I, Schindelin H. Structural insights into E1-catalyzed ubiquitin 
activation and transfer to conjugating enzymes. Cell 2008 134: 268–78 
113. Jaremko L, Jaremko M, Wojciechowski W, Filipek R, Szczepanowski 
RH, et al. NMR assignment of a structurally uncharacterised fragment of 
recombinant mouse ubiquitin-activating enzyme. J Biomol. NMR 2006; 
36 Suppl 143. 
114. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence 
weighting, position-specific gap penalties and weight matrix choice. Nuc 
Acids Res. 1994 22: 4673–80. 
115. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, et al. Protein 
structure homology modeling using SWISS-MODEL workspace. Nat 
Protoc. 2009; 4(1):1–13. 
116. Kabsch W, Sander C. Biopolymers. 1983; 22:2577–637. 
117. Peitsch MC. ProMod and Swiss-Model: Internet-based tools for 
automated comparative protein modelling. Biochem Soc Trans. 1996; 
24:274–79.  
118. Van Gunsteren WF, Berendsen HJC. Computer simulation of molecular 
dynamics: Methodology, applications, and perspective in Chemistr 
Angew. Chem Int Ed. 1990; 29:992–1023. 
119. Luthy R, Bowie JU, Eisenberg D.Assessment of protein models with 
three-dimensional profiles. Nature 1992; 356:83–5. 
120. Colovos C, Yeates TO. Verification of protein structures: patterns of 
nonbonded atomic interactions. Prot Sci 1993; 2:1511–9.  
121. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a 
program to check the stereochemical quality of protein structures. J Appl 
Cryst. 1993; 26:283–91. 
122. Hooft RWW, Vriend G, Sander C, Abola EE. Errors in protein structure. 
Nature 1996; 381:272. 
123. Bezsonova I, Bruce MC, Wiesner S, Lin H, Rotin D, et al. Interactions 
between the three CIN85 SH3 domains and ubiquitin: implications for 
CIN85 ubiquitination. Biochemistry 2008; 47:8937–49. 
 111 
 
124. Lin Y, Hwang WC, Basavappa R. Structural and Functional Analysis of 
the Human Mitotic-specific Ubiquitin-conjugating Enzyme, UbcH10. J 
Biol Chem. 2002; 277:21913–21. 
125. Olsen SK, Lima CD. Structure of a ubiquitin E1–E2 complex: Insights to 
E1–E2 thioesther transfer. Mol Cell 2013; 49:884–96. 
126. Kortemme T, Kim DE, Baker D. Computational alanine scanning of 
protein-protein interfaces. Sci STKE 2004; 219: pl2.  
127. Huo S, Massova I, Kollman PA. Computational alanine scanning of the 
1:1 human growth hormone receptor complex. J Comput Chem. 2002; 
23:15–27. 
128. Amato F, Tomaiuolo R, Nici F, Borbone N, Elce A, Catalanotti B, 
D'Errico S, Morgillo CM, De Rosa G, Mayol L, Piccialli G, Oliviero G, 
Castaldo G. Exploitation of a very small peptide nucleic acid as a new 
inhibitor of miR-509-3p involved in the regulation of cystic fibrosis 
disease-gene expression. Biomed Res Int. 2014:610718. 
129. Bader AG, Brown D, Winkler M. The promise of microRNA replacement 
therapy. Cancer Res. 2010; 70(18):7027–30.  
130. Costinean S, Zanesi N, Pekarsky Y et al. Pre-B cell proliferation and 
lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic 
mice. Proc  Natl Acad Sci. USA 2006; 103(18):7024–9.  
131. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-
155 for normal immune function. Science 2007; 316(5824):608–11.  
132. Brown PN, Yin H. PNA-based microRNA inhibitors elicit anti-
inflammatory effects in microglia cells. Chem Comm. 2013; 49:4415–7.  
133. Ullah S, John P, Bhatti A. MicroRNAs with a role in gene regulation and 
in human diseases. Mol Biol. Rep. 2013 
134. Li Y, Kowdley KV. MicroRNAs in common human diseases,” Gen Prot 
Bioinf. 2012; 10:246–53. 
135. McIntosh I, Cutting GR. Cystic fibrosis transmembrane conductance 
regulator and the etiology and pathogenesis of cystic fibrosis. FASEB 
1992; 6(10):2775–82.   
136. Gillen AE, Gosalia N, Leir SH, Harris A. microRNA regulation of 
expression of the cystic fibrosis transmembrane conductance regulator 
gene,” Biochem. 2011; 438(1):25–32.   
137. Amato F, Seia M, Giordano S, et al. Gene mutation in microRNA target 
sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis? 
PLoS ONE, 2013; 8:e60448. 
138. 22-33 
139. Brognara E, Fabbri E, Aimi F, et al. Peptide nucleic acids targeting miR-
221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. 
Int J Onc. 2012; 41:2119–27. 
140. Torres AG, Fabani MM, Vigorito E et al. Chemical structure 
requirements and cellular targeting of microRNA-122 by peptide nucleic 
acids anti-miRs, Nuc Acids Res. 2012; 40(5):2152–67.   
141. Fabani MM, Abreu-Goodger C, Williams D et al. Efficient inhibition of 
miR-155 function in vivo by peptide nucleic acids. Nuc Acids Res. 2010; 
38(13):4466–75.   
142. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective 
recognition of DNA by strand displacement with thymine-substituted 
polyamide. Science, 1991; 254(5037):1497–1500.   
 112 
 
143. Pooga M, Land T, Bartfai T, Langel U. PNA oligomers as tools for 
specific modulation of gene expression. Biomol Eng. 2001; 17(6):183–
192.   
144. Zhang X, Ishihara T, Corey DR. Strand invasion by mixed base PNAs 
and a PNA-peptide chimera. Nuc Acids Res. 2000; 28(17):3332–8.   
145. Kushon SA, Jordan JP, Seifert JL, Nielsen H, Nielsen PE, Armitage BA. 
Effect of secondary structure on the thermodynamics and kinetics of PNA 
hybridization to DNA hairpins. J Am Chem Soc. 2001; 123(44):10805–
13.   
146. Besch R, Giovannangeli C, Schuh T, Kammerbauer C, Degitz K, 
Characterization and quantification of triple helix formation in 
chromosomal DNA. J Mol Biol. 2004; 341(4):979–989.   
147. Nielsen PE. Peptide Nucleic Acids (PNA) in chemical biology and drug 
discovery. Chem Biodivers. 2010; 7(4):786–804.   
148. Amato J, Stellato MI, Pizzo E, et al. PNA as a potential modulator of 
COL7A1 gene expression in dominant dystrophic epidermolysis bullosa: 
a physico-chemical study. Mol BioSyst. 2013.   
149. Amato J, Oliviero G, de Pauw GE, Gabelica V. Hybridization of short 
complementary PNAs to G-quadruplex forming oligonucleotides: an 
electrospray mass spectrometry study. Biopolymers, 2009; 91(4):244–55.   
150. Amato J, Pagano B, Borbone N et al. Targeting G-Quadruplex structure 
in the human c-Kit promoter with short PNA sequences. Bioconj Chem. 
2011; 22(4):654–63.  
151. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular 
disease: opportunities and obstacles. Nat Rev Drug Disc. 2012; 11:860–
72. 
152. Gaglione M, Milano G, Chambery A, Moggio L, Romanelli A, Messere 
A. PNA-based artificial nucleases as antisense and anti-miRNA 
oligonucleotide agents. Mol BioSyst. 2011; 7(8):2490–9.   
153. Manicardi A, Fabbri E, Tedeschi T, et al. Cellular uptakes, biostabilities 
and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 
cells. Chem Bio Chem. 2012; 13:1327–37. 
154. Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by 
seed-targeting tiny LNAs. Nat Genet. 2011; 43(4):371–80. 
155. Brennecke J, Stark A, Russell RB, Cohen SM. Silencing of microRNA 
families by seed-targeting tiny LNAs. Nat Genet. 2011; 43:371–8.  
156. Patrick DM, Montgomery RL, Qi X et al. Stress-dependent cardiac 
remodeling occurs in the absence of microRNA-21 in mice. J Clin 
Investig. 2010; 120(11):3912–6. 
157. Brown SC, Thomson SA, Veal JM, Davis DG. NMR solution structure of 
a peptide nucleic acid complexed with RNA. Science, 1994; 
265(5173):777–80. 
158. Soliva R, Sherer E, Luque FJ, Laughton CA, Orozco M. Molecular 
dynamics simulations of PNA·DNA and PNA·RNA duplexes in aqueous 
solution. J Am Chem Soc.  2000; 122(25):5997–6008. 
159. Elkayam E, Kuhn CD, Tocilj A, et al. The structure of human argonaute-2 
in complex with miR-20a. Cell 2012; 150:100–10. 
160. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. 
Comparison of multiple amber force fields and development of improved 
protein backbone parameters. Proteins, 2006; 65(3):712–25.  
 113 
 
161. Sanders JM, Wampole ME, Chen CP, et al. Effects of hypoxanthine 
substitution in peptide nucleic acids targeting KRAS2 oncogenic mRNA 
molecules: theory and experiment. J Phys Chem B 2013.   
162. Dupradeau FY, Cézard C, Lelong R et al. R.E.DD.B.: a database for 
RESP and ESP atomic charges, and force field libraries. Nuc Acids Res. 
2008; 36(1):D360–D367.   
163. Craft Jr JW, Legge GB. An AMBER/DYANA/MOLMOL 
phosphorylated amino acid library set and incorporation into NMR 
structure calculations. J Biomol NMR, 2005; 33(1):15–24. 
164. Lavery R, Moakher M, Maddocks JH, Petkeviciute D, Zakrzewska K. 
Conformational analysis of nucleic acids revisited: curves+. Nuc Acids 
Res. 1996; 37(17):5917–29.   
165. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J 
Mol Graph. 1996; 14(1):33–8. 
 
